{
    "id": 769,
    "name": "neuroblastoma",
    "source": "DOID",
    "definition": "An autonomic nervous system neoplasm that derives_from immature nerve cells. [url:http\\://www.cancer.gov/cancertopics/types/neuroblastoma]",
    "currentPreferredTerm": null,
    "lastUpdateDateFromDO": "03/24/2020",
    "altIds": [
        
    ],
    "termId": "DOID:769",
    "evidence": [
        {
            "id": 858,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Istodax (romidepsin) inhibited cell growth of neuroblastoma cell lines with Myc amplification (PMID: 20404560).",
            "molecularProfile": {
                "id": 1426,
                "profileName": "MYC amp"
            },
            "therapy": {
                "id": 1075,
                "therapyName": "Romidepsin",
                "synonyms": null
            },
            "indication": {
                "id": 769,
                "name": "neuroblastoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 515,
                    "pubMedId": 20404560,
                    "title": "Romidepsin (FK228/depsipeptide) controls growth and induces apoptosis in neuroblastoma tumor cells.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/20404560"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 859,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclincal study, Depakene (valproic acid) enhanced the cytotoxicity of ellipticine in human neuroblastoma cell lines (PMID: 22167207).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 1677,
                "therapyName": "Ellipticine + Valproic acid",
                "synonyms": null
            },
            "indication": {
                "id": 769,
                "name": "neuroblastoma",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 516,
                    "pubMedId": 22167207,
                    "title": "Anticancer agent ellipticine combined with histone deacetylase inhibitors, valproic acid and trichostatin A, is an effective DNA damage strategy in human neuroblastoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/22167207"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 865,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Zolinza (vorinostat) displayed efficacy in human neuroblastoma cell lines in culture and in xenografts, including those resistant to Adriamycin (doxorubicin) (PMID: 22703804).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 1077,
                "therapyName": "Vorinostat",
                "synonyms": null
            },
            "indication": {
                "id": 769,
                "name": "neuroblastoma",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 521,
                    "pubMedId": 22703804,
                    "title": "Efficacy of class I and II vs class III histone deacetylase inhibitors in neuroblastoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/22703804"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 1092,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, GW441756, a TrkA inhibitor, blocked tyrosine phosphorylation of ERK and JNK induced by TrkA over expression in neuroblastoma cells (PMID: 23319303).",
            "molecularProfile": {
                "id": 1855,
                "profileName": "NTRK1 over exp"
            },
            "therapy": {
                "id": 1533,
                "therapyName": "GW441756",
                "synonyms": null
            },
            "indication": {
                "id": 769,
                "name": "neuroblastoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 824,
                    "pubMedId": 23319303,
                    "title": "Proteomic analysis of novel targets associated with TrkA-mediated tyrosine phosphorylation signaling pathways in SK-N-MC neuroblastoma cells.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/23319303"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 1166,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, CD532 inhibited cell growth of MYCN-amplified neuroblastoma cell lines significantly more than nonamplified lines (PMID: 25175806).",
            "molecularProfile": {
                "id": 478,
                "profileName": "MYCN amp"
            },
            "therapy": {
                "id": 1628,
                "therapyName": "CD532",
                "synonyms": null
            },
            "indication": {
                "id": 769,
                "name": "neuroblastoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 913,
                    "pubMedId": 25175806,
                    "title": "Drugging MYCN through an allosteric transition in Aurora kinase A.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25175806"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 1169,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, MYCN amplification was found to be a dominant predictor of JQ1 response as evidenced by increased survival in three different models of MYCN amplified neuroblastoma (PMID: 23430699).",
            "molecularProfile": {
                "id": 478,
                "profileName": "MYCN amp"
            },
            "therapy": {
                "id": 1574,
                "therapyName": "JQ1",
                "synonyms": null
            },
            "indication": {
                "id": 769,
                "name": "neuroblastoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 914,
                    "pubMedId": 23430699,
                    "title": "Targeting MYCN in neuroblastoma by BET bromodomain inhibition.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/23430699"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 1170,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, CCT137690 inhibited MYCN amplified neuroblastoma cell lines in vitro more potently than non MYCN amplified lines and inhibited tumor growth in a MYCN-driven transgenic mouse model of neuroblastoma (PMID: 21885865).",
            "molecularProfile": {
                "id": 478,
                "profileName": "MYCN amp"
            },
            "therapy": {
                "id": 1629,
                "therapyName": "CCT137690",
                "synonyms": null
            },
            "indication": {
                "id": 769,
                "name": "neuroblastoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 916,
                    "pubMedId": 21885865,
                    "title": "The aurora kinase inhibitor CCT137690 downregulates MYCN and sensitizes MYCN-amplified neuroblastoma in vivo.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/21885865"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 1416,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Kisqali (ribociclib) demonstrated sensitivity in a set of neuroblastoma cell lines and xenograft models, which express CDK4/6 and display active CDK4/6 signalling, and harbor amplification of MYCN (PMID: 24045179).",
            "molecularProfile": {
                "id": 2488,
                "profileName": "CDK6 pos MYCN amp"
            },
            "therapy": {
                "id": 790,
                "therapyName": "Ribociclib",
                "synonyms": null
            },
            "indication": {
                "id": 769,
                "name": "neuroblastoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 828,
                    "pubMedId": 24045179,
                    "title": "Dual CDK4/CDK6 inhibition induces cell-cycle arrest and senescence in neuroblastoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/24045179"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 1451,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Kisqali (ribociclib) demonstrated sensitivity in a set of neuroblastoma cell lines and xenograft models, which express CDK4/6 and displays active CDK4/6 signalling, and harbor amplification of MYCN (PMID: 24045179).",
            "molecularProfile": {
                "id": 2528,
                "profileName": "CDK4 pos MYCN amp"
            },
            "therapy": {
                "id": 790,
                "therapyName": "Ribociclib",
                "synonyms": null
            },
            "indication": {
                "id": 769,
                "name": "neuroblastoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 828,
                    "pubMedId": 24045179,
                    "title": "Dual CDK4/CDK6 inhibition induces cell-cycle arrest and senescence in neuroblastoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/24045179"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 1491,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, KLF4 overexpression in combination with apigenin (APG) treatment induced apoptosis and suppressed the cell migration in neuroblastoma cell lines (PMID: 23317647).",
            "molecularProfile": {
                "id": 2605,
                "profileName": "KLF4 over exp"
            },
            "therapy": {
                "id": 1810,
                "therapyName": "Apigenin",
                "synonyms": null
            },
            "indication": {
                "id": 769,
                "name": "neuroblastoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 1402,
                    "pubMedId": 23317647,
                    "title": "KLF4 overexpression and apigenin treatment down regulated anti-apoptotic Bcl-2 proteins and matrix metalloproteinases to control growth of human malignant neuroblastoma SK-N-DZ and IMR-32 cells.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/23317647"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 1736,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the combination of NVP-CGM097 and Zykadia (NVP-LDK378) decreased MYCN protein in MYCN-amplified human neuroblastoma cell lines in culture and induced tumor regression in cell line xenograft models (Cancer Res 2014; 74 (19 Suppl); Abstract nr 2929).",
            "molecularProfile": {
                "id": 478,
                "profileName": "MYCN amp"
            },
            "therapy": {
                "id": 2148,
                "therapyName": "Ceritinib + CGM097",
                "synonyms": null
            },
            "indication": {
                "id": 769,
                "name": "neuroblastoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 1982,
                    "pubMedId": null,
                    "title": "The Mdm2 inhibitor NVP-CGM097 enhances the anti-tumor activity of NVP-LDK378 in ALK mutant neuroblastoma models",
                    "url": "http://cancerres.aacrjournals.org/content/74/19_Supplement/2929"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 1745,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Roscovitine (Seliciclib) significantly decreased MYCN expression in neuroblastoma cell lines harboring MYCN amplifications (PMID: 24317512).",
            "molecularProfile": {
                "id": 478,
                "profileName": "MYCN amp"
            },
            "therapy": {
                "id": 1129,
                "therapyName": "Seliciclib",
                "synonyms": null
            },
            "indication": {
                "id": 769,
                "name": "neuroblastoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 1995,
                    "pubMedId": 24317512,
                    "title": "CDK/CK1 inhibitors roscovitine and CR8 downregulate amplified MYCN in neuroblastoma cells.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/24317512"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 2804,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, PW12 inhibited growth of MYCN-amplified neuroblastoma cells in culture and reduced tumor growth in mouse models of MYCN-amplified neuroblastoma (PMID: 26029667).",
            "molecularProfile": {
                "id": 478,
                "profileName": "MYCN amp"
            },
            "therapy": {
                "id": 2961,
                "therapyName": "PW12",
                "synonyms": null
            },
            "indication": {
                "id": 769,
                "name": "neuroblastoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 3486,
                    "pubMedId": 26029667,
                    "title": "Downregulation of MYCN through PI3K Inhibition in Mouse Models of Pediatric Neural Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26029667"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 2991,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, nutlin-3 inhibited growth of neuroblastoma cell lines harboring MYCN amplification (PMID: 21725357).",
            "molecularProfile": {
                "id": 478,
                "profileName": "MYCN amp"
            },
            "therapy": {
                "id": 1405,
                "therapyName": "Nutlin-3",
                "synonyms": null
            },
            "indication": {
                "id": 769,
                "name": "neuroblastoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 3556,
                    "pubMedId": 21725357,
                    "title": "MYCN sensitizes neuroblastoma to the MDM2-p53 antagonists Nutlin-3 and MI-63.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/21725357"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 2992,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, MI-63 inhibited growth of neuroblastoma cell lines harboring MYCN amplification (PMID: 21725357).",
            "molecularProfile": {
                "id": 478,
                "profileName": "MYCN amp"
            },
            "therapy": {
                "id": 1582,
                "therapyName": "MI-63",
                "synonyms": null
            },
            "indication": {
                "id": 769,
                "name": "neuroblastoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 3556,
                    "pubMedId": 21725357,
                    "title": "MYCN sensitizes neuroblastoma to the MDM2-p53 antagonists Nutlin-3 and MI-63.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/21725357"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 2993,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, neuroblastoma cell lines harboring TP53 mutant were resistant to nutlin-3 mediated growth inhibition (PMID: 21725357).",
            "molecularProfile": {
                "id": 434,
                "profileName": "TP53 mutant"
            },
            "therapy": {
                "id": 1405,
                "therapyName": "Nutlin-3",
                "synonyms": null
            },
            "indication": {
                "id": 769,
                "name": "neuroblastoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 3556,
                    "pubMedId": 21725357,
                    "title": "MYCN sensitizes neuroblastoma to the MDM2-p53 antagonists Nutlin-3 and MI-63.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/21725357"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 2994,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, neuroblastoma cell lines harboring TP53 mutant were resistant to MI-63 mediated growth inhibition (PMID: 21725357).",
            "molecularProfile": {
                "id": 434,
                "profileName": "TP53 mutant"
            },
            "therapy": {
                "id": 1582,
                "therapyName": "MI-63",
                "synonyms": null
            },
            "indication": {
                "id": 769,
                "name": "neuroblastoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 3556,
                    "pubMedId": 21725357,
                    "title": "MYCN sensitizes neuroblastoma to the MDM2-p53 antagonists Nutlin-3 and MI-63.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/21725357"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 3216,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the pan-Notch inhibitor, BMS-906024, inhibited growth of neuroblastoma xenografts (PMID: 26005526).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 2545,
                "therapyName": "BMS-906024",
                "synonyms": null
            },
            "indication": {
                "id": 769,
                "name": "neuroblastoma",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 3681,
                    "pubMedId": 26005526,
                    "title": "Discovery of Clinical Candidate BMS-906024: A Potent Pan-Notch Inhibitor for the Treatment of Leukemia and Solid Tumors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26005526"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 3294,
            "approvalStatus": "Phase I",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I clinical trial, the combination of 131I-MIBG with Zolinza (vorinostat) as a radiosensitizer demonstrated preliminary efficacy at the recommended Phase II dose, with in an overall objective response rate of 17% (1/6) and MIBG response rate of 67% (4/6) in patients with neuroblastoma (PMID: 25695691).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 1427,
                "therapyName": "131I-MIBG + Vorinostat",
                "synonyms": null
            },
            "indication": {
                "id": 769,
                "name": "neuroblastoma",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 3715,
                    "pubMedId": 25695691,
                    "title": "Phase I Study of Vorinostat as a Radiation Sensitizer with 131I-Metaiodobenzylguanidine (131I-MIBG) for Patients with Relapsed or Refractory Neuroblastoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25695691"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 3412,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, treatment with Alisertib (MLN8237) resulted in complete response in 63% (5/8) of mouse models of MYCN-driven neuroblastoma (PMID: 23792191).",
            "molecularProfile": {
                "id": 13311,
                "profileName": "MYCN over exp"
            },
            "therapy": {
                "id": 626,
                "therapyName": "Alisertib",
                "synonyms": null
            },
            "indication": {
                "id": 769,
                "name": "neuroblastoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 3772,
                    "pubMedId": 23792191,
                    "title": "Small molecule inhibitors of aurora-a induce proteasomal degradation of N-myc in childhood neuroblastoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/23792191"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 3638,
            "approvalStatus": "Preclinical - Pdx & cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, AT7519 inhibited growth of human neuroblastoma cell lines harboring MYCN amplification in culture, and blocked tumor progression in MYCN-amplified patient-derived xenograft models (PMID: 26202950).",
            "molecularProfile": {
                "id": 478,
                "profileName": "MYCN amp"
            },
            "therapy": {
                "id": 2727,
                "therapyName": "AT7519",
                "synonyms": null
            },
            "indication": {
                "id": 769,
                "name": "neuroblastoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 3922,
                    "pubMedId": 26202950,
                    "title": "Cyclin-Dependent Kinase Inhibitor AT7519 as a Potential Drug for MYCN-Dependent Neuroblastoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26202950"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 3944,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, BMS-754807 treatment resulted in significant tumor growth delay in 67% (4/6) of cell line xenograft models of neuroblastoma (PMID: 21298745).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 686,
                "therapyName": "BMS-754807",
                "synonyms": null
            },
            "indication": {
                "id": 769,
                "name": "neuroblastoma",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 4302,
                    "pubMedId": 21298745,
                    "title": "Initial testing (stage 1) of the IGF-1 receptor inhibitor BMS-754807 by the pediatric preclinical testing program.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/21298745"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 3960,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, GNF-4256 treatment inhibited BDNF-induced phosphorylation of Ntrk2 and growth of neuroblastoma cell lines expressing Ntrk2 in culture, and slowed tumor growth in the neuroblastoma cell line xenograft models (PMID: 25394774).",
            "molecularProfile": {
                "id": 5968,
                "profileName": "NTRK2 positive"
            },
            "therapy": {
                "id": 2653,
                "therapyName": "GNF-4256",
                "synonyms": null
            },
            "indication": {
                "id": 769,
                "name": "neuroblastoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 2684,
                    "pubMedId": 25394774,
                    "title": "TrkB inhibition by GNF-4256 slows growth and enhances chemotherapeutic efficacy in neuroblastoma xenografts.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25394774"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 3962,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, GNF-4256 treatment had no effect on the growth of Ntrk2-null neuroblastoma cell lines in culture (PMID: 25394774).",
            "molecularProfile": {
                "id": 16591,
                "profileName": "NTRK2 loss"
            },
            "therapy": {
                "id": 2653,
                "therapyName": "GNF-4256",
                "synonyms": null
            },
            "indication": {
                "id": 769,
                "name": "neuroblastoma",
                "source": "DOID"
            },
            "responseType": "no benefit",
            "references": [
                {
                    "id": 2684,
                    "pubMedId": 25394774,
                    "title": "TrkB inhibition by GNF-4256 slows growth and enhances chemotherapeutic efficacy in neuroblastoma xenografts.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25394774"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 3963,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, GNF-4256 worked synergistically with Camptosar (irinotecan) and Temodar (temozolomide), resulting in growth inhibition and an increased event-free survival in cell line xenograft models of neuroblastoma expressing Ntrk2 (PMID: 25394774).",
            "molecularProfile": {
                "id": 5968,
                "profileName": "NTRK2 positive"
            },
            "therapy": {
                "id": 3407,
                "therapyName": "GNF-4256 + Irinotecan + Temozolomide",
                "synonyms": null
            },
            "indication": {
                "id": 769,
                "name": "neuroblastoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 2684,
                    "pubMedId": 25394774,
                    "title": "TrkB inhibition by GNF-4256 slows growth and enhances chemotherapeutic efficacy in neuroblastoma xenografts.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25394774"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 3971,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, AZ64 in combination with Camptosar (irinotecan) and Temodar (temozolomide) improved event-free survival and reduced tumor growth in neuroblastoma cell line xenograft models over expressing Ntrk2 (TrkB), with increased efficacy over chemotherapy alone (PMID: 22623209).",
            "molecularProfile": {
                "id": 5933,
                "profileName": "NTRK2 over exp"
            },
            "therapy": {
                "id": 3408,
                "therapyName": "AZ64 + Irinotecan + Temozolomide",
                "synonyms": null
            },
            "indication": {
                "id": 769,
                "name": "neuroblastoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 2715,
                    "pubMedId": 22623209,
                    "title": "AZ64 inhibits TrkB and enhances the efficacy of chemotherapy and local radiation in neuroblastoma xenografts.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/22623209"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 4503,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Zolinza (vorinostat) and Adriamycin (doxorubicin) inhibited growth of human neuroblastoma cells in culture and in cell line xenograft models (PMID: 22703804).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 3527,
                "therapyName": "Doxorubicin + Vorinostat",
                "synonyms": null
            },
            "indication": {
                "id": 769,
                "name": "neuroblastoma",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 521,
                    "pubMedId": 22703804,
                    "title": "Efficacy of class I and II vs class III histone deacetylase inhibitors in neuroblastoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/22703804"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 4504,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the combination of Adriamycin (doxorubicin) and Cambinol inhibited growth of a human neuroblastoma cell line in culture and in xenograft models (PMID: 22703804).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 3529,
                "therapyName": "Cambinol + Doxorubicin",
                "synonyms": null
            },
            "indication": {
                "id": 769,
                "name": "neuroblastoma",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 521,
                    "pubMedId": 22703804,
                    "title": "Efficacy of class I and II vs class III histone deacetylase inhibitors in neuroblastoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/22703804"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 4730,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the combination of Xalkori (crizotinib), Topotecan, and Cytoxan (cyclophosphamide) synergized to sustain tumor regression in human neuroblastoma cell line xenograft models harboring ALK R1275Q and wild-type TP53 (PMID: 26438783).",
            "molecularProfile": {
                "id": 1416,
                "profileName": "ALK R1275Q"
            },
            "therapy": {
                "id": 3601,
                "therapyName": "Crizotinib + Cyclophosphamide + Topotecan",
                "synonyms": null
            },
            "indication": {
                "id": 769,
                "name": "neuroblastoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 4681,
                    "pubMedId": 26438783,
                    "title": "Crizotinib Synergizes with Chemotherapy in Preclinical Models of Neuroblastoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26438783"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 4731,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the combination of Xalkori (crizotinib), Topotecan, and Cytoxan (cyclophosphamide) synergized to sustain tumor regression in xenograft models of a crizotinib-resistant human neuroblastoma cell line harboring ALK F1174L and wild-type TP53 (PMID: 26438783).",
            "molecularProfile": {
                "id": 18879,
                "profileName": "ALK F1174L TP53 wild-type"
            },
            "therapy": {
                "id": 3601,
                "therapyName": "Crizotinib + Cyclophosphamide + Topotecan",
                "synonyms": null
            },
            "indication": {
                "id": 769,
                "name": "neuroblastoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 4681,
                    "pubMedId": 26438783,
                    "title": "Crizotinib Synergizes with Chemotherapy in Preclinical Models of Neuroblastoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26438783"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 4732,
            "approvalStatus": "Preclinical - Pdx",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Xalkori (crizotinib) worked synergistically with Topotecan and Cytoxan (cyclophosphamide), resulting in sustained tumor regression in crizotinib-resistant neuroblastoma PDX models harboring ALK F1245C and wild-type Tp53 (PMID: 26438783).",
            "molecularProfile": {
                "id": 18883,
                "profileName": "ALK F1245C TP53 wild-type"
            },
            "therapy": {
                "id": 3601,
                "therapyName": "Crizotinib + Cyclophosphamide + Topotecan",
                "synonyms": null
            },
            "indication": {
                "id": 769,
                "name": "neuroblastoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 4681,
                    "pubMedId": 26438783,
                    "title": "Crizotinib Synergizes with Chemotherapy in Preclinical Models of Neuroblastoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26438783"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 4733,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the combination of Xalkori (crizotinib), Topotecan, and Cytoxan (cyclophosphamide) synergized to delay tumor growth in xenograft models of a human neuroblastoma cell line harboring constitutively phosphorylated wild-type Alk and wild-type TP53 (PMID: 26438783).",
            "molecularProfile": {
                "id": 18886,
                "profileName": "ALK act mut TP53 wild-type"
            },
            "therapy": {
                "id": 3601,
                "therapyName": "Crizotinib + Cyclophosphamide + Topotecan",
                "synonyms": null
            },
            "indication": {
                "id": 769,
                "name": "neuroblastoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 4681,
                    "pubMedId": 26438783,
                    "title": "Crizotinib Synergizes with Chemotherapy in Preclinical Models of Neuroblastoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26438783"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 4734,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Xalkori (crizotinib) did not improve the effect of Topotecan and Cytoxan (cyclophosphamide) on tumor growth suppression in xenograft models of a human neuroblastoma cell line harboring wild-type ALK and TP53 H168R (PMID: 26438783).",
            "molecularProfile": {
                "id": 18884,
                "profileName": "ALK wild-type TP53 H168R"
            },
            "therapy": {
                "id": 3601,
                "therapyName": "Crizotinib + Cyclophosphamide + Topotecan",
                "synonyms": null
            },
            "indication": {
                "id": 769,
                "name": "neuroblastoma",
                "source": "DOID"
            },
            "responseType": "no benefit",
            "references": [
                {
                    "id": 4681,
                    "pubMedId": 26438783,
                    "title": "Crizotinib Synergizes with Chemotherapy in Preclinical Models of Neuroblastoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26438783"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 4735,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Xalkori (crizotinib) did not improve the effect of Topotecan and Cytoxan (cyclophosphamide) on tumor growth suppression in xenograft models of a human neuroblastoma cell line harboring wild-type ALK, wild-type TP53, and MDM2 amplification (PMID: 26438783).",
            "molecularProfile": {
                "id": 18882,
                "profileName": "ALK wild-type MDM2 amp TP53 wild-type"
            },
            "therapy": {
                "id": 3601,
                "therapyName": "Crizotinib + Cyclophosphamide + Topotecan",
                "synonyms": null
            },
            "indication": {
                "id": 769,
                "name": "neuroblastoma",
                "source": "DOID"
            },
            "responseType": "no benefit",
            "references": [
                {
                    "id": 4681,
                    "pubMedId": 26438783,
                    "title": "Crizotinib Synergizes with Chemotherapy in Preclinical Models of Neuroblastoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26438783"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 4736,
            "approvalStatus": "Preclinical - Pdx & cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Xalkori (crizotinib) demonstrated synergy with the combination of Topotecan and Cytoxan (cyclophosphamide) in patient-derived neuroblastoma cell lines harboring Alk mutations and functional TP53, resulting in growth inhibition in culture and tumor regression in animal models (PMID: 26438783).",
            "molecularProfile": {
                "id": 18888,
                "profileName": "ALK mut TP53 wild-type"
            },
            "therapy": {
                "id": 3601,
                "therapyName": "Crizotinib + Cyclophosphamide + Topotecan",
                "synonyms": null
            },
            "indication": {
                "id": 769,
                "name": "neuroblastoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 4681,
                    "pubMedId": 26438783,
                    "title": "Crizotinib Synergizes with Chemotherapy in Preclinical Models of Neuroblastoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26438783"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 4737,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Xalkori (crizotinib) did not demonstrate synergy with the combination of Topotecan and Cytoxan (cyclophosphamide) on growth inhibition in neuroblastoma cell lines harboring wild-tpye Alk and TP53 C176F in culture (PMID: 26438783).",
            "molecularProfile": {
                "id": 18880,
                "profileName": "ALK wild-type TP53 C176F"
            },
            "therapy": {
                "id": 3601,
                "therapyName": "Crizotinib + Cyclophosphamide + Topotecan",
                "synonyms": null
            },
            "indication": {
                "id": 769,
                "name": "neuroblastoma",
                "source": "DOID"
            },
            "responseType": "no benefit",
            "references": [
                {
                    "id": 4681,
                    "pubMedId": 26438783,
                    "title": "Crizotinib Synergizes with Chemotherapy in Preclinical Models of Neuroblastoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26438783"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 4738,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Xalkori (crizotinib) did not demonstrate synergy with the combination of Topotecan and Cytoxan (cyclophosphamide) on growth inhibition in neuroblastoma cell lines harboring wild-tpye Alk and TP53 P177T in culture (PMID: 26438783).",
            "molecularProfile": {
                "id": 18889,
                "profileName": "ALK wild-type TP53 P177T"
            },
            "therapy": {
                "id": 3601,
                "therapyName": "Crizotinib + Cyclophosphamide + Topotecan",
                "synonyms": null
            },
            "indication": {
                "id": 769,
                "name": "neuroblastoma",
                "source": "DOID"
            },
            "responseType": "no benefit",
            "references": [
                {
                    "id": 4681,
                    "pubMedId": 26438783,
                    "title": "Crizotinib Synergizes with Chemotherapy in Preclinical Models of Neuroblastoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26438783"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 4739,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Xalkori (crizotinib) did not demonstrate synergy with the combination of Topotecan and Cytoxan (cyclophosphamide) on growth inhibition in neuroblastoma cell lines harboring wild-tpye Alk and TP53 mutations in culture (PMID: 26438783).",
            "molecularProfile": {
                "id": 18890,
                "profileName": "ALK wild-type TP53 mut"
            },
            "therapy": {
                "id": 3601,
                "therapyName": "Crizotinib + Cyclophosphamide + Topotecan",
                "synonyms": null
            },
            "indication": {
                "id": 769,
                "name": "neuroblastoma",
                "source": "DOID"
            },
            "responseType": "no benefit",
            "references": [
                {
                    "id": 4681,
                    "pubMedId": 26438783,
                    "title": "Crizotinib Synergizes with Chemotherapy in Preclinical Models of Neuroblastoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26438783"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 4740,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Xalkori (crizotinib) demonstrated synergy with the combination of Topotecan and Cytoxan (cyclophosphamide) in neuroblastoma cell lines harboring Alk amplification and functional TP53, resulting in growth inhibition in culture (PMID: 26438783).",
            "molecularProfile": {
                "id": 18891,
                "profileName": "ALK amp TP53 wild-type"
            },
            "therapy": {
                "id": 3601,
                "therapyName": "Crizotinib + Cyclophosphamide + Topotecan",
                "synonyms": null
            },
            "indication": {
                "id": 769,
                "name": "neuroblastoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 4681,
                    "pubMedId": 26438783,
                    "title": "Crizotinib Synergizes with Chemotherapy in Preclinical Models of Neuroblastoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26438783"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 4741,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Xalkori (crizotinib) did not demonstrate synergy with the combination of Topotecan and Cytoxan (cyclophosphamide) on growth inhibition in neuroblastoma cell lines harboring wild-tpye Alk and wild-type TP53 in culture (PMID: 26438783).",
            "molecularProfile": {
                "id": 18892,
                "profileName": "ALK wild-type TP53 wild-type"
            },
            "therapy": {
                "id": 3601,
                "therapyName": "Crizotinib + Cyclophosphamide + Topotecan",
                "synonyms": null
            },
            "indication": {
                "id": 769,
                "name": "neuroblastoma",
                "source": "DOID"
            },
            "responseType": "no benefit",
            "references": [
                {
                    "id": 4681,
                    "pubMedId": 26438783,
                    "title": "Crizotinib Synergizes with Chemotherapy in Preclinical Models of Neuroblastoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26438783"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 4742,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Topotecan and Cytoxan (cyclophosphamide) combination treatment resulted in mild tumor growth delay in a neuroblastoma cell line xenograft model with wild-type ALK and TP53 H168R, and a model with wild-type ALK, wild-type TP53, and MDM2 amplification (PMID: 26438783).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 2590,
                "therapyName": "Cyclophosphamide + Topotecan",
                "synonyms": null
            },
            "indication": {
                "id": 769,
                "name": "neuroblastoma",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 4681,
                    "pubMedId": 26438783,
                    "title": "Crizotinib Synergizes with Chemotherapy in Preclinical Models of Neuroblastoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26438783"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 4991,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, neuroblastoma cells with MYCN amplification demonstrated decreased sensitivity to treatment with GANT61 in culture compared to cells without MYCN amplification (PMID: 22949014).",
            "molecularProfile": {
                "id": 478,
                "profileName": "MYCN amp"
            },
            "therapy": {
                "id": 1786,
                "therapyName": "GANT61",
                "synonyms": null
            },
            "indication": {
                "id": 769,
                "name": "neuroblastoma",
                "source": "DOID"
            },
            "responseType": "decreased response",
            "references": [
                {
                    "id": 4827,
                    "pubMedId": 22949014,
                    "title": "Targeting the hedgehog signal transduction pathway at the level of GLI inhibits neuroblastoma cell growth in vitro and in vivo.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/22949014"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 4992,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, GANT61 induced apoptosis and decreased growth of neuroblastoma cells in culture, and inhibited tumor growth in neuroblastoma cell line xenograft models (PMID: 22949014).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 1786,
                "therapyName": "GANT61",
                "synonyms": null
            },
            "indication": {
                "id": 769,
                "name": "neuroblastoma",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 4827,
                    "pubMedId": 22949014,
                    "title": "Targeting the hedgehog signal transduction pathway at the level of GLI inhibits neuroblastoma cell growth in vitro and in vivo.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/22949014"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 4993,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, GANT61 and Adriamycin (doxorubicin) worked synergistically to inhibit growth of neuroblastoma cells in culture (PMID: 22949014).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 3715,
                "therapyName": "Doxorubicin + GANT61",
                "synonyms": null
            },
            "indication": {
                "id": 769,
                "name": "neuroblastoma",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 4827,
                    "pubMedId": 22949014,
                    "title": "Targeting the hedgehog signal transduction pathway at the level of GLI inhibits neuroblastoma cell growth in vitro and in vivo.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/22949014"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 4994,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, GANT61 and Oncovin (vincristine) worked synergistically to inhibit growth of neuroblastoma cells in culture (PMID: 22949014).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 3716,
                "therapyName": "GANT61 + Vincristine",
                "synonyms": null
            },
            "indication": {
                "id": 769,
                "name": "neuroblastoma",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 4827,
                    "pubMedId": 22949014,
                    "title": "Targeting the hedgehog signal transduction pathway at the level of GLI inhibits neuroblastoma cell growth in vitro and in vivo.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/22949014"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 5282,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, GSK2830371 inhibited proliferation of neuroblastoma cell lines carrying wild-type TP53 in culture (PMID: 25658463).",
            "molecularProfile": {
                "id": 642,
                "profileName": "TP53 wild-type"
            },
            "therapy": {
                "id": 3735,
                "therapyName": "GSK2830371",
                "synonyms": null
            },
            "indication": {
                "id": 769,
                "name": "neuroblastoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 4979,
                    "pubMedId": 25658463,
                    "title": "WIP1 phosphatase as a potential therapeutic target in neuroblastoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25658463"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 5283,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, neuroblastoma cell lines harboring TP53 mutations were resistant to GSK2830371 induced growth inhibition in culture (PMID: 25658463).",
            "molecularProfile": {
                "id": 434,
                "profileName": "TP53 mutant"
            },
            "therapy": {
                "id": 3735,
                "therapyName": "GSK2830371",
                "synonyms": null
            },
            "indication": {
                "id": 769,
                "name": "neuroblastoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 4979,
                    "pubMedId": 25658463,
                    "title": "WIP1 phosphatase as a potential therapeutic target in neuroblastoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25658463"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 5284,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, GSK283071 and Paraplatin (carboplatin) worked synergistically to inhibit proliferation of neuroblastoma cell lines carrying wild-type TP53 (PMID: 25658463).",
            "molecularProfile": {
                "id": 642,
                "profileName": "TP53 wild-type"
            },
            "therapy": {
                "id": 3814,
                "therapyName": "Carboplatin + GSK2830371",
                "synonyms": null
            },
            "indication": {
                "id": 769,
                "name": "neuroblastoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 4979,
                    "pubMedId": 25658463,
                    "title": "WIP1 phosphatase as a potential therapeutic target in neuroblastoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25658463"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 5285,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, GSK283071 and Adriamycin (doxorubicin) worked synergistically to inhibit proliferation of neuroblastoma cell lines carrying wild-type TP53 (PMID: 25658463).",
            "molecularProfile": {
                "id": 642,
                "profileName": "TP53 wild-type"
            },
            "therapy": {
                "id": 3815,
                "therapyName": "Doxorubicin + GSK2830371",
                "synonyms": null
            },
            "indication": {
                "id": 769,
                "name": "neuroblastoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 4979,
                    "pubMedId": 25658463,
                    "title": "WIP1 phosphatase as a potential therapeutic target in neuroblastoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25658463"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 5554,
            "approvalStatus": "Phase I",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I trial, the combination of Alisertib (MLN8237), Camptosar (irinotecan), and Temodar (temozolomide) demonstrated safety and preliminary efficacy in neuroblastoma patients, resulting in an overall response rate of 31.8% and a 2-year progression-free survival rate of 52.4% (PMID: 26884555).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 2628,
                "therapyName": "Alisertib + Irinotecan + Temozolomide",
                "synonyms": null
            },
            "indication": {
                "id": 769,
                "name": "neuroblastoma",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 5102,
                    "pubMedId": 26884555,
                    "title": "Phase I Study of the Aurora A Kinase Inhibitor Alisertib in Combination With Irinotecan and Temozolomide for Patients With Relapsed or Refractory Neuroblastoma: A NANT (New Approaches to Neuroblastoma Therapy) Trial.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26884555"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 15463,
            "approvalStatus": "Phase II",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase II trial, the combination of Alisertib (MLN8237), Camptosar (irinotecan), and Temodar (temozolomide) resulted in a response rate of 21.1% (4/19) in patients with neuroblastoma, with 4 partial responses, 2 minor responses, and 5 stable diseases (PMID: 30093449; NCT01601535).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 2628,
                "therapyName": "Alisertib + Irinotecan + Temozolomide",
                "synonyms": null
            },
            "indication": {
                "id": 769,
                "name": "neuroblastoma",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 13334,
                    "pubMedId": 30093449,
                    "title": "Phase II Trial of Alisertib in Combination with Irinotecan and Temozolomide for Patients with Relapsed or Refractory Neuroblastoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30093449"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 5609,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, THZ1 inhibited proliferation of MYCN-amplified neuroblastoma cell lines in culture and suppressed tumor growth in MYCN-amplified neuroblastoma cell line xenograft models (PMID: 25416950).",
            "molecularProfile": {
                "id": 478,
                "profileName": "MYCN amp"
            },
            "therapy": {
                "id": 3908,
                "therapyName": "THZ1",
                "synonyms": null
            },
            "indication": {
                "id": 769,
                "name": "neuroblastoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 5125,
                    "pubMedId": 25416950,
                    "title": "CDK7 inhibition suppresses super-enhancer-linked oncogenic transcription in MYCN-driven cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25416950"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 5611,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, THZ1 inhibited proliferation of MYCN-overexpressing neuroblastoma cell lines in culture (PMID: 25416950).",
            "molecularProfile": {
                "id": 13311,
                "profileName": "MYCN over exp"
            },
            "therapy": {
                "id": 3908,
                "therapyName": "THZ1",
                "synonyms": null
            },
            "indication": {
                "id": 769,
                "name": "neuroblastoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 5125,
                    "pubMedId": 25416950,
                    "title": "CDK7 inhibition suppresses super-enhancer-linked oncogenic transcription in MYCN-driven cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25416950"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 5880,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, neuroblastoma cells harboring ALK F1174V were sensitive to Alunbrig (brigatinib) in culture and in vivo, resulting in inhibition of both Alk activity and cell proliferation (PMID: 27049722).",
            "molecularProfile": {
                "id": 3081,
                "profileName": "ALK F1174V"
            },
            "therapy": {
                "id": 634,
                "therapyName": "Brigatinib",
                "synonyms": null
            },
            "indication": {
                "id": 769,
                "name": "neuroblastoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 5182,
                    "pubMedId": 27049722,
                    "title": "Brigatinib, an anaplastic lymphoma kinase inhibitor, abrogates activity and growth in ALK-positive neuroblastoma cells, Drosophila and mice.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27049722"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 5889,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, MYCN amplified neuroblastoma cells were sensitive to Navitoclax (ABT-263) in culture, resulting in inhibition of cell growth (PMID: 26859456).",
            "molecularProfile": {
                "id": 478,
                "profileName": "MYCN amp"
            },
            "therapy": {
                "id": 825,
                "therapyName": "Navitoclax",
                "synonyms": null
            },
            "indication": {
                "id": 769,
                "name": "neuroblastoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 5184,
                    "pubMedId": 26859456,
                    "title": "Exploitation of the Apoptosis-Primed State of MYCN-Amplified Neuroblastoma to Develop a Potent and Specific Targeted Therapy Combination.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26859456"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 5890,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, MYCN amplified neuroblastoma cells were sensitive to Venclexta (venetoclax) in culture, resulting in inhibition of cell growth (PMID: 26859456).",
            "molecularProfile": {
                "id": 478,
                "profileName": "MYCN amp"
            },
            "therapy": {
                "id": 1562,
                "therapyName": "Venetoclax",
                "synonyms": null
            },
            "indication": {
                "id": 769,
                "name": "neuroblastoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 5184,
                    "pubMedId": 26859456,
                    "title": "Exploitation of the Apoptosis-Primed State of MYCN-Amplified Neuroblastoma to Develop a Potent and Specific Targeted Therapy Combination.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26859456"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 5892,
            "approvalStatus": "Preclinical - Pdx & cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, MYCN amplified neuroblastoma cells were sensitive to the combination of Venclexta (venetoclax) and Alisertib (MLN8237) in both culture and cell line xenograft models, as well as a patient derived xenograft (PDX) model of neuroblastoma, resulting in high levels of apoptosis, cell growth arrest, and tumor regression (PMID: 26859456).",
            "molecularProfile": {
                "id": 478,
                "profileName": "MYCN amp"
            },
            "therapy": {
                "id": 3972,
                "therapyName": "Alisertib + Venetoclax",
                "synonyms": null
            },
            "indication": {
                "id": 769,
                "name": "neuroblastoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 5184,
                    "pubMedId": 26859456,
                    "title": "Exploitation of the Apoptosis-Primed State of MYCN-Amplified Neuroblastoma to Develop a Potent and Specific Targeted Therapy Combination.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26859456"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 5893,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, MYCN amplified neuroblastoma cells were sensitive to the combination of Venclexta (venetoclax) and Tozasertib (VX-680) in culture, resulting in high levels of apoptosis and cell growth arrest (PMID: 26859456).",
            "molecularProfile": {
                "id": 478,
                "profileName": "MYCN amp"
            },
            "therapy": {
                "id": 3973,
                "therapyName": "Tozasertib + Venetoclax",
                "synonyms": null
            },
            "indication": {
                "id": 769,
                "name": "neuroblastoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 5184,
                    "pubMedId": 26859456,
                    "title": "Exploitation of the Apoptosis-Primed State of MYCN-Amplified Neuroblastoma to Develop a Potent and Specific Targeted Therapy Combination.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26859456"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 6586,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, JQ1 and Farydak (panobinostat) worked synergistically to induce apoptosis and alter expression of target genes in MYCN-amplified human neuroblastoma cell lines in culture and to reduce Mycn expression and decrease tumor growth in MYCN-amplified neuroblastoma xenograft models (PMID: 26733615).",
            "molecularProfile": {
                "id": 478,
                "profileName": "MYCN amp"
            },
            "therapy": {
                "id": 4185,
                "therapyName": "JQ1 + Panobinostat",
                "synonyms": null
            },
            "indication": {
                "id": 769,
                "name": "neuroblastoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 5706,
                    "pubMedId": 26733615,
                    "title": "The Bromodomain Inhibitor JQ1 and the Histone Deacetylase Inhibitor Panobinostat Synergistically Reduce N-Myc Expression and Induce Anticancer Effects.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26733615"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 7015,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, SANT1 inhibited survival of neuroblastoma cell lines with elevated GLI2 and SHH mRNA levels in culture (PMID: 26781311).",
            "molecularProfile": {
                "id": 24358,
                "profileName": "GLI2 over exp SHH over exp"
            },
            "therapy": {
                "id": 3990,
                "therapyName": "SANT1",
                "synonyms": null
            },
            "indication": {
                "id": 769,
                "name": "neuroblastoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 6046,
                    "pubMedId": 26781311,
                    "title": "Targeting hedgehog signaling pathway in pediatric tumors: in vitro evaluation of SMO and GLI inhibitors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26781311"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 7157,
            "approvalStatus": "Phase I",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I trial, treatment with the combination of Alisertib (MLN8237), Camptosar (irinotecan), and Temodar (temozolomide) demonstrated safety and resulted in an overall response rate of 31.8%, with a response rate of 35.7% in patients with MYCN-nonamplified tumors, and 16.7% in patients with MYCN amplification (PMID: 26884555).",
            "molecularProfile": {
                "id": 478,
                "profileName": "MYCN amp"
            },
            "therapy": {
                "id": 2628,
                "therapyName": "Alisertib + Irinotecan + Temozolomide",
                "synonyms": null
            },
            "indication": {
                "id": 769,
                "name": "neuroblastoma",
                "source": "DOID"
            },
            "responseType": "decreased response",
            "references": [
                {
                    "id": 5102,
                    "pubMedId": 26884555,
                    "title": "Phase I Study of the Aurora A Kinase Inhibitor Alisertib in Combination With Irinotecan and Temozolomide for Patients With Relapsed or Refractory Neuroblastoma: A NANT (New Approaches to Neuroblastoma Therapy) Trial.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26884555"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 15481,
            "approvalStatus": "Phase II",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase II trial, the combination of Alisertib (MLN8237), Camptosar (irinotecan), and Temodar (temozolomide) resulted in decreased 1-year progression-free survival rate (10% vs 47%, p=0.018) in neuroblastoma patients with MYCN amplification compared to patients without MYCN amplification (PMID: 30093449; NCT01601535).",
            "molecularProfile": {
                "id": 478,
                "profileName": "MYCN amp"
            },
            "therapy": {
                "id": 2628,
                "therapyName": "Alisertib + Irinotecan + Temozolomide",
                "synonyms": null
            },
            "indication": {
                "id": 769,
                "name": "neuroblastoma",
                "source": "DOID"
            },
            "responseType": "decreased response",
            "references": [
                {
                    "id": 13334,
                    "pubMedId": 30093449,
                    "title": "Phase II Trial of Alisertib in Combination with Irinotecan and Temozolomide for Patients with Relapsed or Refractory Neuroblastoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30093449"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 7619,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, 10058-F4 induced apoptosis and inhibited growth of MYCN-amplified neuroblastoma cell lines in culture (PMID: 24859015).",
            "molecularProfile": {
                "id": 478,
                "profileName": "MYCN amp"
            },
            "therapy": {
                "id": 3304,
                "therapyName": "10058-F4",
                "synonyms": null
            },
            "indication": {
                "id": 769,
                "name": "neuroblastoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6446,
                    "pubMedId": 24859015,
                    "title": "Targeting of the MYCN protein with small molecule c-MYC inhibitors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/24859015"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 7810,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Tarceva (erlotinib) inhibited Egfr phosphorylation and cell proliferation in neuroblastoma cells over expressing EGFR T34_A289del in culture (PMID: 27216155).",
            "molecularProfile": {
                "id": 26048,
                "profileName": "EGFR T34_A289del"
            },
            "therapy": {
                "id": 4,
                "therapyName": "Erlotinib",
                "synonyms": null
            },
            "indication": {
                "id": 769,
                "name": "neuroblastoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6503,
                    "pubMedId": 27216155,
                    "title": "A Novel EGFR Extracellular Domain Mutant, EGFR\u0394768, Possesses Distinct Biological and Biochemical Properties in Neuroblastoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27216155"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 7812,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, neuroblastoma cells over expressing EGFR T34_A289del were resistant to Eposin (etoposide) in culture (PMID: 27216155).",
            "molecularProfile": {
                "id": 26048,
                "profileName": "EGFR T34_A289del"
            },
            "therapy": {
                "id": 1136,
                "therapyName": "Etoposide",
                "synonyms": null
            },
            "indication": {
                "id": 769,
                "name": "neuroblastoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 6503,
                    "pubMedId": 27216155,
                    "title": "A Novel EGFR Extracellular Domain Mutant, EGFR\u0394768, Possesses Distinct Biological and Biochemical Properties in Neuroblastoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27216155"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 8155,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, a TH-MYCN neuroblastoma mouse model demonstrated sensitivity to treatment with SAM486, which showed delayed tumor development (PMID: 27012811).",
            "molecularProfile": {
                "id": 13311,
                "profileName": "MYCN over exp"
            },
            "therapy": {
                "id": 4649,
                "therapyName": "SAM486",
                "synonyms": null
            },
            "indication": {
                "id": 769,
                "name": "neuroblastoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6562,
                    "pubMedId": 27012811,
                    "title": "Polyamine Antagonist Therapies Inhibit Neuroblastoma Initiation and Progression.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27012811"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 8156,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, a TH-MYCN neuroblastoma mouse model demonstrated greater sensitivity to the combination treatment of Eflornithine and SAM486 compared to SAM486 alone, which showed a longer delay in tumor development and greater percentage reduction of tumor penetrance (PMID: 27012811).",
            "molecularProfile": {
                "id": 13311,
                "profileName": "MYCN over exp"
            },
            "therapy": {
                "id": 4650,
                "therapyName": "Eflornithine + SAM486",
                "synonyms": null
            },
            "indication": {
                "id": 769,
                "name": "neuroblastoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6562,
                    "pubMedId": 27012811,
                    "title": "Polyamine Antagonist Therapies Inhibit Neuroblastoma Initiation and Progression.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27012811"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 8328,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, MYCN-amplified neuroblastoma cell lines demonstrated increased sensitivity to Birabresib (OTX015) compared to non-amplified cell lines in culture and in cell line xenograft models (PMID: 26631615).",
            "molecularProfile": {
                "id": 478,
                "profileName": "MYCN amp"
            },
            "therapy": {
                "id": 2034,
                "therapyName": "Birabresib",
                "synonyms": null
            },
            "indication": {
                "id": 769,
                "name": "neuroblastoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6614,
                    "pubMedId": 26631615,
                    "title": "Targeting MYCN-Driven Transcription By BET-Bromodomain Inhibition.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26631615"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 8369,
            "approvalStatus": "Preclinical - Pdx & cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Xalkori (crizotinib) did not inhibit growth of neuroblastoma cells over expressing ALK F1174L in culture, and only delayed tumor growth in patient-derived and cell line xenograft models harboring ALK F1174L (PMID: 26554404).",
            "molecularProfile": {
                "id": 698,
                "profileName": "ALK F1174L"
            },
            "therapy": {
                "id": 706,
                "therapyName": "Crizotinib",
                "synonyms": null
            },
            "indication": {
                "id": 769,
                "name": "neuroblastoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 6636,
                    "pubMedId": 26554404,
                    "title": "The ALK/ROS1 Inhibitor PF-06463922 Overcomes Primary Resistance to Crizotinib in ALK-Driven Neuroblastoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26554404"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 8370,
            "approvalStatus": "Preclinical - Pdx & cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Xalkori (crizotinib) did not inhibit growth of neuroblastoma cells over expressing ALK F1245C in culture, and only delayed tumor growth in patient-derived xenograft models harboring ALK F1245C (PMID: 26554404).",
            "molecularProfile": {
                "id": 1414,
                "profileName": "ALK F1245C"
            },
            "therapy": {
                "id": 706,
                "therapyName": "Crizotinib",
                "synonyms": null
            },
            "indication": {
                "id": 769,
                "name": "neuroblastoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 6636,
                    "pubMedId": 26554404,
                    "title": "The ALK/ROS1 Inhibitor PF-06463922 Overcomes Primary Resistance to Crizotinib in ALK-Driven Neuroblastoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26554404"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 14244,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Xalkori (crizotinib) inhibited proliferation of neuroblastoma cells harboring ALK R1275Q in culture (PMID: 29907598).",
            "molecularProfile": {
                "id": 1416,
                "profileName": "ALK R1275Q"
            },
            "therapy": {
                "id": 706,
                "therapyName": "Crizotinib",
                "synonyms": null
            },
            "indication": {
                "id": 769,
                "name": "neuroblastoma",
                "source": "DOID"
            },
            "responseType": "conflicting",
            "references": [
                {
                    "id": 11556,
                    "pubMedId": 29907598,
                    "title": "Clinical response of the novel activating ALK-I1171T mutation in neuroblastoma to the ALK inhibitor ceritinib.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29907598"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 8371,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Xalkori (crizotinib) did not inhibit growth of neuroblastoma cells over expressing ALK R1275Q in culture, and only delayed tumor growth in cell line xenograft models (PMID: 26554404).",
            "molecularProfile": {
                "id": 1416,
                "profileName": "ALK R1275Q"
            },
            "therapy": {
                "id": 706,
                "therapyName": "Crizotinib",
                "synonyms": null
            },
            "indication": {
                "id": 769,
                "name": "neuroblastoma",
                "source": "DOID"
            },
            "responseType": "conflicting",
            "references": [
                {
                    "id": 6636,
                    "pubMedId": 26554404,
                    "title": "The ALK/ROS1 Inhibitor PF-06463922 Overcomes Primary Resistance to Crizotinib in ALK-Driven Neuroblastoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26554404"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 8372,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Xalkori (crizotinib) did not inhibit growth of neuroblastoma cells over expressing EML4-ALK in culture (PMID: 26554404).",
            "molecularProfile": {
                "id": 4138,
                "profileName": "EML4 - ALK"
            },
            "therapy": {
                "id": 706,
                "therapyName": "Crizotinib",
                "synonyms": null
            },
            "indication": {
                "id": 769,
                "name": "neuroblastoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 6636,
                    "pubMedId": 26554404,
                    "title": "The ALK/ROS1 Inhibitor PF-06463922 Overcomes Primary Resistance to Crizotinib in ALK-Driven Neuroblastoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26554404"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 8373,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Xalkori (crizotinib) was less efficient than Lorlatinib (PF-06463922) to induced growth inhibition in ALK-amplified neuroblastoma cells in culture (PMID: 26554404).",
            "molecularProfile": {
                "id": 1760,
                "profileName": "ALK amp"
            },
            "therapy": {
                "id": 706,
                "therapyName": "Crizotinib",
                "synonyms": null
            },
            "indication": {
                "id": 769,
                "name": "neuroblastoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6636,
                    "pubMedId": 26554404,
                    "title": "The ALK/ROS1 Inhibitor PF-06463922 Overcomes Primary Resistance to Crizotinib in ALK-Driven Neuroblastoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26554404"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 15497,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, neuroblastoma cells harboring ALK F1174L were resistant to Lorbrena (lorlatinib) in culture (PMID: 30322862).",
            "molecularProfile": {
                "id": 698,
                "profileName": "ALK F1174L"
            },
            "therapy": {
                "id": 869,
                "therapyName": "Lorlatinib",
                "synonyms": null
            },
            "indication": {
                "id": 769,
                "name": "neuroblastoma",
                "source": "DOID"
            },
            "responseType": "conflicting",
            "references": [
                {
                    "id": 13404,
                    "pubMedId": 30322862,
                    "title": "Lorlatinib Treatment Elicits Multiple On- and Off-Target Mechanisms of Resistance in ALK-Driven Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30322862"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 8374,
            "approvalStatus": "Preclinical - Pdx & cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Lorbrena (lorlatinib) inhibited growth of neuroblastoma cells over expressing ALK F1174L in culture, and induced rapid and sustained complete tumor regression in both patient-derived and cell line xenograft models harboring ALK F1174L (PMID: 26554404).",
            "molecularProfile": {
                "id": 698,
                "profileName": "ALK F1174L"
            },
            "therapy": {
                "id": 869,
                "therapyName": "Lorlatinib",
                "synonyms": null
            },
            "indication": {
                "id": 769,
                "name": "neuroblastoma",
                "source": "DOID"
            },
            "responseType": "conflicting",
            "references": [
                {
                    "id": 6636,
                    "pubMedId": 26554404,
                    "title": "The ALK/ROS1 Inhibitor PF-06463922 Overcomes Primary Resistance to Crizotinib in ALK-Driven Neuroblastoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26554404"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 8375,
            "approvalStatus": "Preclinical - Pdx & cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Lorlatinib (PF-06463922) inhibited growth of neuroblastoma cells over expressing ALK F1245C in culture, and induced rapid and sustained complete tumor regression in patient-derived xenograft models harboring ALK F1245C (PMID: 26554404).",
            "molecularProfile": {
                "id": 1414,
                "profileName": "ALK F1245C"
            },
            "therapy": {
                "id": 869,
                "therapyName": "Lorlatinib",
                "synonyms": null
            },
            "indication": {
                "id": 769,
                "name": "neuroblastoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6636,
                    "pubMedId": 26554404,
                    "title": "The ALK/ROS1 Inhibitor PF-06463922 Overcomes Primary Resistance to Crizotinib in ALK-Driven Neuroblastoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26554404"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 8376,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Lorbrena (lorlatinib) inhibited Alk phosphorylation, resulted in growth inhibition of neuroblastoma cells over expressing ALK R1275Q in culture and irapid and sustained complete tumor regression in cell line xenograft models (PMID: 26554404).",
            "molecularProfile": {
                "id": 1416,
                "profileName": "ALK R1275Q"
            },
            "therapy": {
                "id": 869,
                "therapyName": "Lorlatinib",
                "synonyms": null
            },
            "indication": {
                "id": 769,
                "name": "neuroblastoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6636,
                    "pubMedId": 26554404,
                    "title": "The ALK/ROS1 Inhibitor PF-06463922 Overcomes Primary Resistance to Crizotinib in ALK-Driven Neuroblastoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26554404"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 8378,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Lorlatinib (PF-06463922) inhibited growth of neuroblastoma cells harboring EML4-ALK in culture (PMID: 26554404).",
            "molecularProfile": {
                "id": 4138,
                "profileName": "EML4 - ALK"
            },
            "therapy": {
                "id": 869,
                "therapyName": "Lorlatinib",
                "synonyms": null
            },
            "indication": {
                "id": 769,
                "name": "neuroblastoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6636,
                    "pubMedId": 26554404,
                    "title": "The ALK/ROS1 Inhibitor PF-06463922 Overcomes Primary Resistance to Crizotinib in ALK-Driven Neuroblastoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26554404"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 8379,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Lorlatinib (PF-06463922) inhibited growth of ALK amplified neuroblastoma cells in culture (PMID: 26554404).",
            "molecularProfile": {
                "id": 1760,
                "profileName": "ALK amp"
            },
            "therapy": {
                "id": 869,
                "therapyName": "Lorlatinib",
                "synonyms": null
            },
            "indication": {
                "id": 769,
                "name": "neuroblastoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6636,
                    "pubMedId": 26554404,
                    "title": "The ALK/ROS1 Inhibitor PF-06463922 Overcomes Primary Resistance to Crizotinib in ALK-Driven Neuroblastoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26554404"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 8380,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Lorlatinib (PF-06463922) did not inhibit growth of ALK wild-type neuroblastoma cells in culture (PMID: 26554404).",
            "molecularProfile": {
                "id": 391,
                "profileName": "ALK wild-type"
            },
            "therapy": {
                "id": 869,
                "therapyName": "Lorlatinib",
                "synonyms": null
            },
            "indication": {
                "id": 769,
                "name": "neuroblastoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 6636,
                    "pubMedId": 26554404,
                    "title": "The ALK/ROS1 Inhibitor PF-06463922 Overcomes Primary Resistance to Crizotinib in ALK-Driven Neuroblastoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26554404"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 8624,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, a neuroblastoma cell line over expressing MDM2 and wild-type for TP53 demonstrated sensitivity to treatment with MX69 in culture, resulting in decreased cell survival (PMID: 27666947).",
            "molecularProfile": {
                "id": 26380,
                "profileName": "MDM2 over exp TP53 wild-type"
            },
            "therapy": {
                "id": 4775,
                "therapyName": "MX69",
                "synonyms": null
            },
            "indication": {
                "id": 769,
                "name": "neuroblastoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6705,
                    "pubMedId": 27666947,
                    "title": "Discovery of Dual Inhibitors of MDM2 and XIAP for Cancer Treatment.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27666947"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 9082,
            "approvalStatus": "FDA approved",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase III trial supporting FDA approval, Unituxin (dinutuximab) in combination with Sargramostim, Aldesleukin, and 13-cis-retinoic acid resulted in improved median event-free survival (HR = 0.57) and overall survival (HR = 0.58) compared to control group in high-risk pediatric neuroblastoma patients (PMID: 26917818).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 2286,
                "therapyName": "Dinutuximab",
                "synonyms": null
            },
            "indication": {
                "id": 769,
                "name": "neuroblastoma",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 6898,
                    "pubMedId": 26917818,
                    "title": "Dinutuximab: An Anti-GD2 Monoclonal Antibody for High-Risk Neuroblastoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26917818"
                },
                {
                    "id": 15647,
                    "pubMedId": null,
                    "title": "Unituxin (dinutuximab) FDA Drug Label",
                    "url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=125516"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 9125,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Fenretinide and ABT-751 synergistically inhibited growth of neuroblastoma cell lines in culture and in cell line xenograft models (PMID: 27530131).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 4909,
                "therapyName": "ABT-751 + Fenretinide",
                "synonyms": null
            },
            "indication": {
                "id": 769,
                "name": "neuroblastoma",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 6926,
                    "pubMedId": 27530131,
                    "title": "Reactive Oxygen Species Mediates the Synergistic Activity of Fenretinide Combined with the Microtubule Inhibitor ABT-751 against Multidrug-Resistant Recurrent Neuroblastoma Xenografts.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27530131"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 9212,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, AZ64 inhibited tumor growth in neuroblastoma cell line xenograft models over expressing Ntrk2 (TrkB) (PMID: 22623209).",
            "molecularProfile": {
                "id": 5933,
                "profileName": "NTRK2 over exp"
            },
            "therapy": {
                "id": 2679,
                "therapyName": "AZ64",
                "synonyms": null
            },
            "indication": {
                "id": 769,
                "name": "neuroblastoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 2715,
                    "pubMedId": 22623209,
                    "title": "AZ64 inhibits TrkB and enhances the efficacy of chemotherapy and local radiation in neuroblastoma xenografts.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/22623209"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 9503,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, NU7026 enhanced radiosensitivity in PRKDC-expressing neuroblastoma cell lines in culture, resulting in decreased cell viability (PMID: 26716839).",
            "molecularProfile": {
                "id": 26861,
                "profileName": "PRKDC positive"
            },
            "therapy": {
                "id": 5043,
                "therapyName": "NU7026 + Radiotherapy",
                "synonyms": null
            },
            "indication": {
                "id": 769,
                "name": "neuroblastoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 7230,
                    "pubMedId": 26716839,
                    "title": "DNA-Dependent Protein Kinase As Molecular Target for Radiosensitization of Neuroblastoma Cells.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26716839"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 9551,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, SRA737 (CCT245737) resulted in decreased tumor volume in a neuroblastoma transgenic mouse model over expressing MYCN (PMID: 27167172).",
            "molecularProfile": {
                "id": 13311,
                "profileName": "MYCN over exp"
            },
            "therapy": {
                "id": 5069,
                "therapyName": "SRA737",
                "synonyms": null
            },
            "indication": {
                "id": 769,
                "name": "neuroblastoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 7267,
                    "pubMedId": 27167172,
                    "title": "Multiparameter Lead Optimization to Give an Oral Checkpoint Kinase 1 (CHK1) Inhibitor Clinical Candidate: (R)-5-((4-((Morpholin-2-ylmethyl)amino)-5-(trifluoromethyl)pyridin-2-yl)amino)pyrazine-2-carbonitrile (CCT245737).",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27167172"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 9666,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the addition of BGB-324 to treatment with Zykadia (ceritinib) increased Zykadia (ceritinib)-induced apoptosis in an AXL-expressing neuroblastoma cell line harboring ALK R1275Q in culture (PMID: 25450694).",
            "molecularProfile": {
                "id": 26949,
                "profileName": "ALK R1275Q AXL pos"
            },
            "therapy": {
                "id": 5124,
                "therapyName": "BGB-324 + Ceritinib",
                "synonyms": null
            },
            "indication": {
                "id": 769,
                "name": "neuroblastoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 7382,
                    "pubMedId": 25450694,
                    "title": "Inhibition of Axl improves the targeted therapy against ALK-mutated neuroblastoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25450694"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 9667,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the addition of BGB-324 to Xalkori (crizotinib) treatment increased Xalkori (crizotinib)-induced apoptosis in an AXL-expressing neuroblastoma cell line harboring ALK R1275Q in culture, and improved efficacy in xenograft models (PMID: 25450694).",
            "molecularProfile": {
                "id": 26949,
                "profileName": "ALK R1275Q AXL pos"
            },
            "therapy": {
                "id": 5123,
                "therapyName": "BGB-324 + Crizotinib",
                "synonyms": null
            },
            "indication": {
                "id": 769,
                "name": "neuroblastoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 7382,
                    "pubMedId": 25450694,
                    "title": "Inhibition of Axl improves the targeted therapy against ALK-mutated neuroblastoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25450694"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 9668,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the addition of BGB-324 to treatment with Zykadia (ceritinib) increased Zykadia (ceritinib)-induced apoptosis in an AXL-expressing neuroblastoma cell line harboring ALK F1174L in culture (PMID: 25450694).",
            "molecularProfile": {
                "id": 26950,
                "profileName": "ALK F1174L AXL pos"
            },
            "therapy": {
                "id": 5124,
                "therapyName": "BGB-324 + Ceritinib",
                "synonyms": null
            },
            "indication": {
                "id": 769,
                "name": "neuroblastoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 7382,
                    "pubMedId": 25450694,
                    "title": "Inhibition of Axl improves the targeted therapy against ALK-mutated neuroblastoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25450694"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 9669,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the addition of BGB-324 to treatment with Xalkori (crizotinib) increased Xalkori (crizotinib)-induced apoptosis in an AXL-expressing neuroblastoma cell line harboring ALK F1147L in culture (PMID: 25450694).",
            "molecularProfile": {
                "id": 26950,
                "profileName": "ALK F1174L AXL pos"
            },
            "therapy": {
                "id": 5123,
                "therapyName": "BGB-324 + Crizotinib",
                "synonyms": null
            },
            "indication": {
                "id": 769,
                "name": "neuroblastoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 7382,
                    "pubMedId": 25450694,
                    "title": "Inhibition of Axl improves the targeted therapy against ALK-mutated neuroblastoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25450694"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 10127,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, verteporfin inhibited growth and metastasis of neuroblastoma cell lines in culture, and pretreatment of a metastatic subpopulation of a neuroblastoma cell line with verteporfin decreased metastasis in xenograft models (PMID: 27899382).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 3319,
                "therapyName": "Verteporfin",
                "synonyms": null
            },
            "indication": {
                "id": 769,
                "name": "neuroblastoma",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 8115,
                    "pubMedId": 27899382,
                    "title": "A Metastatic Mouse Model Identifies Genes That Regulate Neuroblastoma Metastasis.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27899382"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 10349,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I trial, Rozlytrek (entrectinib) treatment resulted in partial response in a patient with ALK-positive neuroblastoma (J Clin Oncol 32:5s, 2014 (suppl; abstr 2502)).",
            "molecularProfile": {
                "id": 1772,
                "profileName": "ALK positive"
            },
            "therapy": {
                "id": 1455,
                "therapyName": "Entrectinib",
                "synonyms": null
            },
            "indication": {
                "id": 769,
                "name": "neuroblastoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 8339,
                    "pubMedId": null,
                    "title": "Phase 1 open label, dose escalation study of RXDX101, an oral pan-trk, ROS1, and ALK inhibitor, in patients with advanced solid tumors with relevant molecular alterations.",
                    "url": "http://meetinglibrary.asco.org/content/131059-144"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 10394,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclincial study, PHA-680632, in combination with Cisplatin, decreased survival of neuroblastoma cells in culture, to a greater extent than Cisplatin alone (PMID: 27256407).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 5504,
                "therapyName": "Cisplatin + PHA-680632",
                "synonyms": null
            },
            "indication": {
                "id": 769,
                "name": "neuroblastoma",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 8416,
                    "pubMedId": 27256407,
                    "title": "Combined cisplatin and aurora inhibitor treatment increase neuroblastoma cell death but surviving cells overproduce BDNF.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27256407"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 10489,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical study, combined analysis of 2 Phase I trials showed Rozlytrek (entrectinib) treatment to result in a partial response that lasted 8.3 months in a patient with neuroblastoma harboring ALK F1245V, who remained on treatment for over 3.5 years due to clinical benefit (PMID: 28183697).",
            "molecularProfile": {
                "id": 27527,
                "profileName": "ALK F1245V"
            },
            "therapy": {
                "id": 1455,
                "therapyName": "Entrectinib",
                "synonyms": null
            },
            "indication": {
                "id": 769,
                "name": "neuroblastoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 8566,
                    "pubMedId": 28183697,
                    "title": "Safety and Antitumor Activity of the Multitargeted Pan-TRK, ROS1, and ALK Inhibitor Entrectinib: Combined Results from Two Phase I Trials (ALKA-372-001 and STARTRK-1).",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28183697"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 10671,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Go 6983 decreased growth of a neuroblastoma cell line in culture (PMID: 10209967).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 2290,
                "therapyName": "Go 6983",
                "synonyms": null
            },
            "indication": {
                "id": 769,
                "name": "neuroblastoma",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 8731,
                    "pubMedId": 10209967,
                    "title": "Novel and classical protein kinase C isoforms have different functions in proliferation, survival and differentiation of neuroblastoma cells.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/10209967"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 10672,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, GF109203X decreased growth of neuroblastoma cell lines in culture (PMID: 10209967).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 2293,
                "therapyName": "GF109203X",
                "synonyms": null
            },
            "indication": {
                "id": 769,
                "name": "neuroblastoma",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 8731,
                    "pubMedId": 10209967,
                    "title": "Novel and classical protein kinase C isoforms have different functions in proliferation, survival and differentiation of neuroblastoma cells.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/10209967"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 10870,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, a neuroblastoma cell line harboring MYCN amplification demonstrated reduced cell viability when treated with FK866 in culture (PMID: 27076630).",
            "molecularProfile": {
                "id": 478,
                "profileName": "MYCN amp"
            },
            "therapy": {
                "id": 5662,
                "therapyName": "FK866",
                "synonyms": null
            },
            "indication": {
                "id": 769,
                "name": "neuroblastoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 8871,
                    "pubMedId": 27076630,
                    "title": "Myc-Driven Glycolysis Is a Therapeutic Target in Glioblastoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27076630"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 10871,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, a neuroblastoma cell line harboring MYCN amplification demonstrated reduced cell viability when treated with GMX1778 in culture (PMID: 27076630).",
            "molecularProfile": {
                "id": 478,
                "profileName": "MYCN amp"
            },
            "therapy": {
                "id": 5666,
                "therapyName": "GMX1778",
                "synonyms": null
            },
            "indication": {
                "id": 769,
                "name": "neuroblastoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 8871,
                    "pubMedId": 27076630,
                    "title": "Myc-Driven Glycolysis Is a Therapeutic Target in Glioblastoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27076630"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 11056,
            "approvalStatus": "Phase I",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I trial, Kisqali (ribociclib) treatment demonstrated safety and resulted in stable disease in 28% (9/32) of pediatric patients with neuroblastoma or malignant rhabdoid tumor (MRT) (7 patients with neuroblastoma and 2 with CNS primary MRT), and 5 patients demonstrated stable disease for greater than 6 months (PMID: 28432176).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 790,
                "therapyName": "Ribociclib",
                "synonyms": null
            },
            "indication": {
                "id": 769,
                "name": "neuroblastoma",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 9051,
                    "pubMedId": 28432176,
                    "title": "A Phase I Study of the CDK4/6 Inhibitor Ribociclib (LEE011) in Pediatric Patients with Malignant Rhabdoid Tumors, Neuroblastoma, and Other Solid Tumors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28432176"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 11448,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Alecensa (alectinib) treatment in a neuroblastoma cell line harboring ALK D1091N resulted in decreased cell viability, inhibition of colony formation, and inhibition of Pi3k pathway signaling in culture (PMID: 28455243).",
            "molecularProfile": {
                "id": 23761,
                "profileName": "ALK D1091N"
            },
            "therapy": {
                "id": 698,
                "therapyName": "Alectinib",
                "synonyms": null
            },
            "indication": {
                "id": 769,
                "name": "neuroblastoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 9400,
                    "pubMedId": 28455243,
                    "title": "The second-generation ALK inhibitor alectinib effectively induces apoptosis in human neuroblastoma cells and inhibits tumor growth in a TH-MYCN transgenic neuroblastoma mouse model.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28455243"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 11449,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Alecensa (alectinib) treatment enhanced the cytotoxic effects of Adriamycin (doxorubicin) in a neuroblastoma cell line harboring ALK D1091N, demonstrating increased apoptotic activity and decreased cell viability in culture (PMID: 28455243).",
            "molecularProfile": {
                "id": 23761,
                "profileName": "ALK D1091N"
            },
            "therapy": {
                "id": 5989,
                "therapyName": "Alectinib + Doxorubicin",
                "synonyms": null
            },
            "indication": {
                "id": 769,
                "name": "neuroblastoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 9400,
                    "pubMedId": 28455243,
                    "title": "The second-generation ALK inhibitor alectinib effectively induces apoptosis in human neuroblastoma cells and inhibits tumor growth in a TH-MYCN transgenic neuroblastoma mouse model.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28455243"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 11450,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, AZD3463 treatment in a neuroblastoma cell line harboring ALK D1091N resulted in inhibition of colony formation, repression of Pi3k signaling, and induction of apoptosis in culture (PMID: 26786851).",
            "molecularProfile": {
                "id": 23761,
                "profileName": "ALK D1091N"
            },
            "therapy": {
                "id": 1586,
                "therapyName": "AZD3463",
                "synonyms": null
            },
            "indication": {
                "id": 769,
                "name": "neuroblastoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 7594,
                    "pubMedId": 26786851,
                    "title": "Novel ALK inhibitor AZD3463 inhibits neuroblastoma growth by overcoming crizotinib resistance and inducing apoptosis.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26786851"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 11451,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, AZD3463 treatment enhanced the cytotoxic effects of Adriamycin (doxorubicin) in a neuroblastoma cell line harboring ALK D1091N, demonstrating increased apoptotic activity and decreased cell viability in culture (PMID: 28455243).",
            "molecularProfile": {
                "id": 23761,
                "profileName": "ALK D1091N"
            },
            "therapy": {
                "id": 5990,
                "therapyName": "AZD3463 + Doxorubicin",
                "synonyms": null
            },
            "indication": {
                "id": 769,
                "name": "neuroblastoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 9400,
                    "pubMedId": 28455243,
                    "title": "The second-generation ALK inhibitor alectinib effectively induces apoptosis in human neuroblastoma cells and inhibits tumor growth in a TH-MYCN transgenic neuroblastoma mouse model.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28455243"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 11540,
            "approvalStatus": "Phase II",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase II trial, treatment with Temodar (temozolomide), Camptosaur (irinotecan), and Avastin (bevacizumab) in combination did not demonstrate benefit over data for Temodar (temozolomide) and Camptosaur (irinotecan) combination therapy, resulting in complete response in 9% (3/33), no response in 55% (18/33), and progressive disease in 36% (12/33) of patients with refractory or relapsed neuroblastoma (PMID: 28111925; NCT01114555).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 1463,
                "therapyName": "Bevacizumab + Irinotecan + Temozolomide",
                "synonyms": null
            },
            "indication": {
                "id": 769,
                "name": "neuroblastoma",
                "source": "DOID"
            },
            "responseType": "no benefit",
            "references": [
                {
                    "id": 9609,
                    "pubMedId": 28111925,
                    "title": "Combination of bevacizumab, irinotecan, and temozolomide for refractory or relapsed neuroblastoma: Results of a phase II study.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28111925"
                }
            ],
            "ampCapAscoEvidenceLevel": "B",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 11757,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Prexasertib (LY2606368) decreased proliferation and increased apoptosis of neuroblastoma cell lines in culture, and induced tumor regression in neuroblastoma cell line xenograft models (PMID: 28270495).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 1651,
                "therapyName": "Prexasertib",
                "synonyms": null
            },
            "indication": {
                "id": 769,
                "name": "neuroblastoma",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 9764,
                    "pubMedId": 28270495,
                    "title": "The Checkpoint Kinase 1 Inhibitor Prexasertib Induces Regression of Preclinical Models of Human Neuroblastoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28270495"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 11758,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the combination of Adriamycin (doxorubicin) and Prexasertib (LY2606368) did not demonstrate benefit over Prexasertib (LY2606368) alone in neuroblastoma cell line xenograft models (PMID: 28270495).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 6142,
                "therapyName": "Doxorubicin + Prexasertib",
                "synonyms": null
            },
            "indication": {
                "id": 769,
                "name": "neuroblastoma",
                "source": "DOID"
            },
            "responseType": "no benefit",
            "references": [
                {
                    "id": 9764,
                    "pubMedId": 28270495,
                    "title": "The Checkpoint Kinase 1 Inhibitor Prexasertib Induces Regression of Preclinical Models of Human Neuroblastoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28270495"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 11850,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, a neuroblastoma transgenic mouse model overexpressing MYCN demonstrated a decrease in tumor volume when treated with CCT244747 (PMID: 22929806).",
            "molecularProfile": {
                "id": 13311,
                "profileName": "MYCN over exp"
            },
            "therapy": {
                "id": 4672,
                "therapyName": "CCT244747",
                "synonyms": null
            },
            "indication": {
                "id": 769,
                "name": "neuroblastoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6590,
                    "pubMedId": 22929806,
                    "title": "CCT244747 is a novel potent and selective CHK1 inhibitor with oral efficacy alone and in combination with genotoxic anticancer drugs.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/22929806"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 12756,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, expression of ALK L1198P in neuroblastoma cells harboring an ALK F1174L mutation resulted in resistance to Xalkori (crizotinib) in culture (PMID: 21948233).",
            "molecularProfile": {
                "id": 28913,
                "profileName": "ALK F1174L ALK L1198P"
            },
            "therapy": {
                "id": 706,
                "therapyName": "Crizotinib",
                "synonyms": null
            },
            "indication": {
                "id": 769,
                "name": "neuroblastoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 5841,
                    "pubMedId": 21948233,
                    "title": "ALK mutations conferring differential resistance to structurally diverse ALK inhibitors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/21948233"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 12757,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, expression of ALK G1123S in neuroblastoma cells harboring an ALK F1174L mutation resulted in resistance to TAE684 in culture (PMID: 21948233).",
            "molecularProfile": {
                "id": 28914,
                "profileName": "ALK G1123S ALK F1174L"
            },
            "therapy": {
                "id": 2386,
                "therapyName": "TAE684",
                "synonyms": null
            },
            "indication": {
                "id": 769,
                "name": "neuroblastoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 5841,
                    "pubMedId": 21948233,
                    "title": "ALK mutations conferring differential resistance to structurally diverse ALK inhibitors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/21948233"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 12758,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, expression of ALK L1198P in neuroblastoma cells harboring an ALK F1174L mutation resulted in resistance to TAE684 in culture (PMID: 21948233).",
            "molecularProfile": {
                "id": 28913,
                "profileName": "ALK F1174L ALK L1198P"
            },
            "therapy": {
                "id": 2386,
                "therapyName": "TAE684",
                "synonyms": null
            },
            "indication": {
                "id": 769,
                "name": "neuroblastoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 5841,
                    "pubMedId": 21948233,
                    "title": "ALK mutations conferring differential resistance to structurally diverse ALK inhibitors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/21948233"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 12759,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, expression of ALK G1123D in neuroblastoma cells harboring an ALK F1174L mutation resulted in resistance to TAE684 in culture (PMID: 21948233).",
            "molecularProfile": {
                "id": 28916,
                "profileName": "ALK G1123D ALK F1174L"
            },
            "therapy": {
                "id": 2386,
                "therapyName": "TAE684",
                "synonyms": null
            },
            "indication": {
                "id": 769,
                "name": "neuroblastoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 5841,
                    "pubMedId": 21948233,
                    "title": "ALK mutations conferring differential resistance to structurally diverse ALK inhibitors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/21948233"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 12798,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, CEP-28122 inhibited growth of neuroblastoma cells harboring ALK R1275Q in culture (PMID: 22203728).",
            "molecularProfile": {
                "id": 1416,
                "profileName": "ALK R1275Q"
            },
            "therapy": {
                "id": 2519,
                "therapyName": "CEP-28122",
                "synonyms": null
            },
            "indication": {
                "id": 769,
                "name": "neuroblastoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 2441,
                    "pubMedId": 22203728,
                    "title": "CEP-28122, a highly potent and selective orally active inhibitor of anaplastic lymphoma kinase with antitumor activity in experimental models of human cancers.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/22203728"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 12799,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, CEP-28122 inhibited growth of neuroblastoma cells harboring ALK F1174L in culture (PMID: 22203728).",
            "molecularProfile": {
                "id": 698,
                "profileName": "ALK F1174L"
            },
            "therapy": {
                "id": 2519,
                "therapyName": "CEP-28122",
                "synonyms": null
            },
            "indication": {
                "id": 769,
                "name": "neuroblastoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 2441,
                    "pubMedId": 22203728,
                    "title": "CEP-28122, a highly potent and selective orally active inhibitor of anaplastic lymphoma kinase with antitumor activity in experimental models of human cancers.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/22203728"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 12800,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, CEP-28122 inhibited growth of ALK-amplified neuroblastoma cells in culture (PMID: 22203728).",
            "molecularProfile": {
                "id": 1760,
                "profileName": "ALK amp"
            },
            "therapy": {
                "id": 2519,
                "therapyName": "CEP-28122",
                "synonyms": null
            },
            "indication": {
                "id": 769,
                "name": "neuroblastoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 2441,
                    "pubMedId": 22203728,
                    "title": "CEP-28122, a highly potent and selective orally active inhibitor of anaplastic lymphoma kinase with antitumor activity in experimental models of human cancers.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/22203728"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 12803,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, CEP-28122 did not inhibit growth of ALK wild-type neuroblastoma cells in culture (PMID: 22203728).",
            "molecularProfile": {
                "id": 391,
                "profileName": "ALK wild-type"
            },
            "therapy": {
                "id": 2519,
                "therapyName": "CEP-28122",
                "synonyms": null
            },
            "indication": {
                "id": 769,
                "name": "neuroblastoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 2441,
                    "pubMedId": 22203728,
                    "title": "CEP-28122, a highly potent and selective orally active inhibitor of anaplastic lymphoma kinase with antitumor activity in experimental models of human cancers.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/22203728"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 13072,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, AZD3463 inhibited growth of neuroblastoma cells harboring ALK F1174L in culture, resulted in near complete tumor regression in cell line xenograft models (PMID: 26786851).",
            "molecularProfile": {
                "id": 698,
                "profileName": "ALK F1174L"
            },
            "therapy": {
                "id": 1586,
                "therapyName": "AZD3463",
                "synonyms": null
            },
            "indication": {
                "id": 769,
                "name": "neuroblastoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 7594,
                    "pubMedId": 26786851,
                    "title": "Novel ALK inhibitor AZD3463 inhibits neuroblastoma growth by overcoming crizotinib resistance and inducing apoptosis.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26786851"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 13086,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, GTx-186 inhibited Erk signaling, resulted in growth inhibition of neuroblastoma cells overexpressing Ntrk1 in culture and in cell line xenograft models (PMID: 24386191).",
            "molecularProfile": {
                "id": 1855,
                "profileName": "NTRK1 over exp"
            },
            "therapy": {
                "id": 2675,
                "therapyName": "GTx-186",
                "synonyms": null
            },
            "indication": {
                "id": 769,
                "name": "neuroblastoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 2718,
                    "pubMedId": 24386191,
                    "title": "Discovery and preclinical characterization of novel small molecule TRK and ROS1 tyrosine kinase inhibitors for the treatment of cancer and inflammation.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/24386191"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 14133,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the combination therapy of Alpelisib (BYL719) and Binimetinib (MEK162) led to a synergistic effect in neuroblastoma cells harboring mutant NRAS, demonstrating cell death in culture (PMID: 29437705).",
            "molecularProfile": {
                "id": 3,
                "profileName": "NRAS mutant"
            },
            "therapy": {
                "id": 1311,
                "therapyName": "Alpelisib + Binimetinib",
                "synonyms": null
            },
            "indication": {
                "id": 769,
                "name": "neuroblastoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 11474,
                    "pubMedId": 29437705,
                    "title": "NRAS-Mutated Rhabdomyosarcoma Cells Are Vulnerable to Mitochondrial Apoptosis Induced by Coinhibition of MEK and PI3K\u03b1.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29437705"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 14239,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Zykadia (ceritinib) inhibited proliferation of neuroblastoma cells harboring ALK amplification and ALK F1174V in culture (PMID: 29907598).",
            "molecularProfile": {
                "id": 29961,
                "profileName": "ALK F1174V ALK amp"
            },
            "therapy": {
                "id": 789,
                "therapyName": "Ceritinib",
                "synonyms": null
            },
            "indication": {
                "id": 769,
                "name": "neuroblastoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 11556,
                    "pubMedId": 29907598,
                    "title": "Clinical response of the novel activating ALK-I1171T mutation in neuroblastoma to the ALK inhibitor ceritinib.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29907598"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 14240,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Zykadia (ceritinib) inhibited proliferation of neuroblastoma cells harboring ALK amplification and ALK F1174L in culture (PMID: 29907598).",
            "molecularProfile": {
                "id": 29962,
                "profileName": "ALK F1174L ALK amp"
            },
            "therapy": {
                "id": 789,
                "therapyName": "Ceritinib",
                "synonyms": null
            },
            "indication": {
                "id": 769,
                "name": "neuroblastoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 11556,
                    "pubMedId": 29907598,
                    "title": "Clinical response of the novel activating ALK-I1171T mutation in neuroblastoma to the ALK inhibitor ceritinib.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29907598"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 14241,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Zykadia (ceritinib) inhibited proliferation of neuroblastoma cells harboring ALK R1275Q in culture (PMID: 29907598).",
            "molecularProfile": {
                "id": 1416,
                "profileName": "ALK R1275Q"
            },
            "therapy": {
                "id": 789,
                "therapyName": "Ceritinib",
                "synonyms": null
            },
            "indication": {
                "id": 769,
                "name": "neuroblastoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 11556,
                    "pubMedId": 29907598,
                    "title": "Clinical response of the novel activating ALK-I1171T mutation in neuroblastoma to the ALK inhibitor ceritinib.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29907598"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 14242,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Xalkori (crizotinib) inhibited proliferation of neuroblastoma cells harboring ALK amplification and ALK F1174V in culture (PMID: 29907598).",
            "molecularProfile": {
                "id": 29961,
                "profileName": "ALK F1174V ALK amp"
            },
            "therapy": {
                "id": 706,
                "therapyName": "Crizotinib",
                "synonyms": null
            },
            "indication": {
                "id": 769,
                "name": "neuroblastoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 11556,
                    "pubMedId": 29907598,
                    "title": "Clinical response of the novel activating ALK-I1171T mutation in neuroblastoma to the ALK inhibitor ceritinib.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29907598"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 14243,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Xalkori (crizotinib) inhibited proliferation of neuroblastoma cells harboring ALK amplification and ALK F1174L in culture (PMID: 29907598).",
            "molecularProfile": {
                "id": 29962,
                "profileName": "ALK F1174L ALK amp"
            },
            "therapy": {
                "id": 706,
                "therapyName": "Crizotinib",
                "synonyms": null
            },
            "indication": {
                "id": 769,
                "name": "neuroblastoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 11556,
                    "pubMedId": 29907598,
                    "title": "Clinical response of the novel activating ALK-I1171T mutation in neuroblastoma to the ALK inhibitor ceritinib.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29907598"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 15501,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, NF1 G2392* was identified as a potential resistance mutation in a neuroblastoma cell line harboring ALK R1275Q that acquired resistance to Lorbrena (lorlatinib) in culture (PMID: 30322862).",
            "molecularProfile": {
                "id": 31076,
                "profileName": "ALK R1275Q NF1 G2392*"
            },
            "therapy": {
                "id": 869,
                "therapyName": "Lorlatinib",
                "synonyms": null
            },
            "indication": {
                "id": 769,
                "name": "neuroblastoma",
                "source": "DOID"
            },
            "responseType": "predicted - resistant",
            "references": [
                {
                    "id": 13404,
                    "pubMedId": 30322862,
                    "title": "Lorlatinib Treatment Elicits Multiple On- and Off-Target Mechanisms of Resistance in ALK-Driven Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30322862"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 15502,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Mekinist (trametinib) restored sensitivity to Lorbrena (lorlatinib) in neuroblastoma cells harboring ALK R1275Q and an acquired NF1 G2392* mutation in culture (PMID: 30322862).",
            "molecularProfile": {
                "id": 31076,
                "profileName": "ALK R1275Q NF1 G2392*"
            },
            "therapy": {
                "id": 7655,
                "therapyName": "Lorlatinib + Trametinib",
                "synonyms": null
            },
            "indication": {
                "id": 769,
                "name": "neuroblastoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 13404,
                    "pubMedId": 30322862,
                    "title": "Lorlatinib Treatment Elicits Multiple On- and Off-Target Mechanisms of Resistance in ALK-Driven Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30322862"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 16618,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, JSH-150 inhibited proliferation of a neuroblastoma cell line in culture (PMID: 30253346).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 8108,
                "therapyName": "JSH-150",
                "synonyms": null
            },
            "indication": {
                "id": 769,
                "name": "neuroblastoma",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 14640,
                    "pubMedId": 30253346,
                    "title": "Discovery of 4-(((4-(5-chloro-2-(((1s,4s)-4-((2-methoxyethyl)amino)cyclohexyl)amino)pyridin-4-yl)thiazol-2-yl)amino)methyl)tetrahydro-2H-pyran-4-carbonitrile (JSH-150) as a novel highly selective and potent CDK9 kinase inhibitor.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30253346"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 17285,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Lynparza (olaparib) treatment of neuroblastoma cells in culture, transfected with Atm P960H, resulted in decreased cell viability as compared to cells carrying wild-type Atm (PMID: 29059438).",
            "molecularProfile": {
                "id": 32474,
                "profileName": "ATM P960H"
            },
            "therapy": {
                "id": 837,
                "therapyName": "Olaparib",
                "synonyms": null
            },
            "indication": {
                "id": 769,
                "name": "neuroblastoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 15336,
                    "pubMedId": 29059438,
                    "title": "Loss of DNA Damage Response in Neuroblastoma and Utility of a PARP Inhibitor.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29059438"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 17286,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Lynparza (olaparib) treatment of neuroblastoma cells in culture, transfected with Atm S1455R, resulted in decreased cell viability as compared to cells carrying wild-type Atm (PMID: 29059438).",
            "molecularProfile": {
                "id": 1419,
                "profileName": "ATM S1455R"
            },
            "therapy": {
                "id": 837,
                "therapyName": "Olaparib",
                "synonyms": null
            },
            "indication": {
                "id": 769,
                "name": "neuroblastoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 15336,
                    "pubMedId": 29059438,
                    "title": "Loss of DNA Damage Response in Neuroblastoma and Utility of a PARP Inhibitor.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29059438"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 17287,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Lynparza (olaparib) treatment of neuroblastoma cells in culture, transfected with Atm V1841I, resulted in decreased cell viability as compared to cells carrying wild-type Atm (PMID: 29059438).",
            "molecularProfile": {
                "id": 32475,
                "profileName": "ATM V1841I"
            },
            "therapy": {
                "id": 837,
                "therapyName": "Olaparib",
                "synonyms": null
            },
            "indication": {
                "id": 769,
                "name": "neuroblastoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 15336,
                    "pubMedId": 29059438,
                    "title": "Loss of DNA Damage Response in Neuroblastoma and Utility of a PARP Inhibitor.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29059438"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 17288,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Lynparza (olaparib) treatment of neuroblastoma cells in culture, transfected with Atm L1874F, resulted in decreased cell viability as compared to cells carrying wild-type Atm (PMID: 29059438).",
            "molecularProfile": {
                "id": 32476,
                "profileName": "ATM L1874F"
            },
            "therapy": {
                "id": 837,
                "therapyName": "Olaparib",
                "synonyms": null
            },
            "indication": {
                "id": 769,
                "name": "neuroblastoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 15336,
                    "pubMedId": 29059438,
                    "title": "Loss of DNA Damage Response in Neuroblastoma and Utility of a PARP Inhibitor.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29059438"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 17289,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Lynparza (olaparib) treatment of neuroblastoma cells in culture, transfected with Atm H2038Y, resulted in decreased cell viability as compared to cells carrying wild-type Atm (PMID: 29059438).",
            "molecularProfile": {
                "id": 25078,
                "profileName": "ATM H2038Y"
            },
            "therapy": {
                "id": 837,
                "therapyName": "Olaparib",
                "synonyms": null
            },
            "indication": {
                "id": 769,
                "name": "neuroblastoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 15336,
                    "pubMedId": 29059438,
                    "title": "Loss of DNA Damage Response in Neuroblastoma and Utility of a PARP Inhibitor.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29059438"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 17290,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Lynparza (olaparib) treatment of neuroblastoma cells in culture, transfected with Atm K2749I, resulted in decreased cell viability as compared to cells carrying wild-type Atm (PMID: 29059438).",
            "molecularProfile": {
                "id": 32481,
                "profileName": "ATM K2749I"
            },
            "therapy": {
                "id": 837,
                "therapyName": "Olaparib",
                "synonyms": null
            },
            "indication": {
                "id": 769,
                "name": "neuroblastoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 15336,
                    "pubMedId": 29059438,
                    "title": "Loss of DNA Damage Response in Neuroblastoma and Utility of a PARP Inhibitor.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29059438"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 17291,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Lynparza (olaparib) treatment of neuroblastoma cells in culture, transfected with Atm A59S, resulted in decreased cell viability as compared to cells carrying wild-type Atm (PMID: 29059438).",
            "molecularProfile": {
                "id": 32477,
                "profileName": "ATM A59S"
            },
            "therapy": {
                "id": 837,
                "therapyName": "Olaparib",
                "synonyms": null
            },
            "indication": {
                "id": 769,
                "name": "neuroblastoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 15336,
                    "pubMedId": 29059438,
                    "title": "Loss of DNA Damage Response in Neuroblastoma and Utility of a PARP Inhibitor.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29059438"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 17292,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Lynparza (olaparib) treatment of neuroblastoma cells in culture, transfected with Atm P604S, resulted in decreased cell viability as compared to cells carrying wild-type Atm (PMID: 29059438).",
            "molecularProfile": {
                "id": 2494,
                "profileName": "ATM P604S"
            },
            "therapy": {
                "id": 837,
                "therapyName": "Olaparib",
                "synonyms": null
            },
            "indication": {
                "id": 769,
                "name": "neuroblastoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 15336,
                    "pubMedId": 29059438,
                    "title": "Loss of DNA Damage Response in Neuroblastoma and Utility of a PARP Inhibitor.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29059438"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 17293,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Lynparza (olaparib) treatment of neuroblastoma cells in culture, transfected with Atm V519I, resulted in decreased cell viability as compared to cells carrying wild-type Atm (PMID: 29059438).",
            "molecularProfile": {
                "id": 32480,
                "profileName": "ATM V519I"
            },
            "therapy": {
                "id": 837,
                "therapyName": "Olaparib",
                "synonyms": null
            },
            "indication": {
                "id": 769,
                "name": "neuroblastoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 15336,
                    "pubMedId": 29059438,
                    "title": "Loss of DNA Damage Response in Neuroblastoma and Utility of a PARP Inhibitor.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29059438"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 17294,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Lynparza (olaparib) treatment of neuroblastoma cells in culture, transfected with Atm S824F, resulted in decreased cell viability as compared to cells carrying wild-type Atm (PMID: 29059438).",
            "molecularProfile": {
                "id": 32479,
                "profileName": "ATM S824F"
            },
            "therapy": {
                "id": 837,
                "therapyName": "Olaparib",
                "synonyms": null
            },
            "indication": {
                "id": 769,
                "name": "neuroblastoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 15336,
                    "pubMedId": 29059438,
                    "title": "Loss of DNA Damage Response in Neuroblastoma and Utility of a PARP Inhibitor.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29059438"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 17295,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Lynparza (olaparib) treatment of neuroblastoma cells in culture, transfected with Atm L1956H, resulted in similar cell viability levels as cells carrying wild-type Atm (PMID: 29059438).",
            "molecularProfile": {
                "id": 32478,
                "profileName": "ATM L1956H"
            },
            "therapy": {
                "id": 837,
                "therapyName": "Olaparib",
                "synonyms": null
            },
            "indication": {
                "id": 769,
                "name": "neuroblastoma",
                "source": "DOID"
            },
            "responseType": "no benefit",
            "references": [
                {
                    "id": 15336,
                    "pubMedId": 29059438,
                    "title": "Loss of DNA Damage Response in Neuroblastoma and Utility of a PARP Inhibitor.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29059438"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 17296,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Lynparza (olaparib) treatment of neuroblastoma cells in culture, transfected with Atm R2691C, resulted in similar cell viability levels as cells carrying wild-type Atm (PMID: 29059438).",
            "molecularProfile": {
                "id": 5710,
                "profileName": "ATM R2691C"
            },
            "therapy": {
                "id": 837,
                "therapyName": "Olaparib",
                "synonyms": null
            },
            "indication": {
                "id": 769,
                "name": "neuroblastoma",
                "source": "DOID"
            },
            "responseType": "no benefit",
            "references": [
                {
                    "id": 15336,
                    "pubMedId": 29059438,
                    "title": "Loss of DNA Damage Response in Neuroblastoma and Utility of a PARP Inhibitor.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29059438"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 19091,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, treatment with UNC1999 resulted in reduced proliferation and increased apoptosis of neuroblastoma cell lines harboring in-frame ATRX fusions in culture, and decreased tumor growth in a neuroblastoma cell line xenograft model harboring an ATRX fusion (PMID: 31631027).",
            "molecularProfile": {
                "id": 33933,
                "profileName": "ATRX fusion"
            },
            "therapy": {
                "id": 1757,
                "therapyName": "UNC1999",
                "synonyms": null
            },
            "indication": {
                "id": 769,
                "name": "neuroblastoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 16742,
                    "pubMedId": 31631027,
                    "title": "ATRX In-Frame Fusion Neuroblastoma Is Sensitive to EZH2 Inhibition via Modulation of Neuronal Gene Signatures.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31631027"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 19095,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, treatment with Tazemetostat (EPZ-6438) resulted in reduced proliferation and increased apoptosis of neuroblastoma cell lines harboring in-frame ATRX fusions in culture (PMID: 31631027).",
            "molecularProfile": {
                "id": 33933,
                "profileName": "ATRX fusion"
            },
            "therapy": {
                "id": 2683,
                "therapyName": "Tazemetostat",
                "synonyms": null
            },
            "indication": {
                "id": 769,
                "name": "neuroblastoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 16742,
                    "pubMedId": 31631027,
                    "title": "ATRX In-Frame Fusion Neuroblastoma Is Sensitive to EZH2 Inhibition via Modulation of Neuronal Gene Signatures.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31631027"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 19096,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, treatment with GSK126 resulted in reduced proliferation and increased apoptosis of neuroblastoma cell lines harboring in-frame ATRX fusions in culture (PMID: 31631027).",
            "molecularProfile": {
                "id": 33933,
                "profileName": "ATRX fusion"
            },
            "therapy": {
                "id": 2925,
                "therapyName": "GSK126",
                "synonyms": null
            },
            "indication": {
                "id": 769,
                "name": "neuroblastoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 16742,
                    "pubMedId": 31631027,
                    "title": "ATRX In-Frame Fusion Neuroblastoma Is Sensitive to EZH2 Inhibition via Modulation of Neuronal Gene Signatures.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31631027"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 19207,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, AOH1160 induced DNA damage, cell cycle arrest, apoptosis, and inhibited proliferation of PCNA-positive neuroblastoma cell lines in culture, and inhibited tumor growth in a cell line xenograft model (PMID: 29967249).",
            "molecularProfile": {
                "id": 33953,
                "profileName": "PCNA positive"
            },
            "therapy": {
                "id": 8907,
                "therapyName": "AOH1160",
                "synonyms": null
            },
            "indication": {
                "id": 769,
                "name": "neuroblastoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 16726,
                    "pubMedId": 29967249,
                    "title": "The Anticancer Activity of a First-in-class Small-molecule Targeting PCNA.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29967249"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 19211,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, PCNA-positive neuroblastoma cell lines demonstrated increased sensitivity to Platinol (cisplatin) when treated in combination with AOH1160, and inhibited colony formation in culture (PMID: 29967249).",
            "molecularProfile": {
                "id": 33953,
                "profileName": "PCNA positive"
            },
            "therapy": {
                "id": 8936,
                "therapyName": "AOH1160 + Cisplatin",
                "synonyms": null
            },
            "indication": {
                "id": 769,
                "name": "neuroblastoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 16726,
                    "pubMedId": 29967249,
                    "title": "The Anticancer Activity of a First-in-class Small-molecule Targeting PCNA.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29967249"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 19871,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, MYCi975 treatment inhibited viability of a Mycn-positive neuroblastoma cell line in culture (PMID: 31679823).",
            "molecularProfile": {
                "id": 26697,
                "profileName": "MYCN positive"
            },
            "therapy": {
                "id": 9235,
                "therapyName": "MYCi975",
                "synonyms": null
            },
            "indication": {
                "id": 769,
                "name": "neuroblastoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 17557,
                    "pubMedId": 31679823,
                    "title": "Small-Molecule MYC Inhibitors Suppress Tumor Growth and Enhance Immunotherapy.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31679823"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 20790,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, OTS167 treatment inhibited proliferation of neuroblastoma cell lines overexpressing MELK in culture, and prolonged survival in a minimal residual disease model and inhibited tumor growth in a cell line xenograft model (PMID: 30674566).",
            "molecularProfile": {
                "id": 21948,
                "profileName": "MELK over exp"
            },
            "therapy": {
                "id": 3951,
                "therapyName": "OTS167",
                "synonyms": null
            },
            "indication": {
                "id": 769,
                "name": "neuroblastoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 18043,
                    "pubMedId": 30674566,
                    "title": "Maternal Embryonic Leucine Zipper Kinase (MELK), a Potential Therapeutic Target for Neuroblastoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30674566"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 20791,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, OTS167 enhanced sensitivity to Camptothecin treatment and synergistically inhibited proliferation of neuroblastoma cell lines overexpressing MELK in culture (PMID: 30674566).",
            "molecularProfile": {
                "id": 21948,
                "profileName": "MELK over exp"
            },
            "therapy": {
                "id": 9449,
                "therapyName": "Camptothecin + OTS167",
                "synonyms": null
            },
            "indication": {
                "id": 769,
                "name": "neuroblastoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 18043,
                    "pubMedId": 30674566,
                    "title": "Maternal Embryonic Leucine Zipper Kinase (MELK), a Potential Therapeutic Target for Neuroblastoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30674566"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        }
    ],
    "clinicalTrials": [
        {
            "nctId": "NCT00084695",
            "title": "Umbilical Cord Blood for Stem Cell Transplantation in Treating Young Patients With Malignant or Nonmalignant Diseases",
            "phase": "Phase II",
            "recruitment": "Unknown status",
            "therapies": [
                {
                    "id": 1166,
                    "therapyName": "Fludarabine",
                    "synonyms": null
                },
                {
                    "id": 2558,
                    "therapyName": "Busulfan + Melphalan",
                    "synonyms": null
                },
                {
                    "id": 1844,
                    "therapyName": "anti-thymocyte globulin",
                    "synonyms": null
                },
                {
                    "id": 1148,
                    "therapyName": "Cyclophosphamide",
                    "synonyms": null
                },
                {
                    "id": 2188,
                    "therapyName": "Prednisone",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT00089245",
            "title": "Radiolabeled Monoclonal Antibody Therapy in Treating Patients With Refractory, Recurrent, or Advanced CNS or Leptomeningeal Cancer",
            "phase": "Phase I",
            "recruitment": "Unknown status",
            "therapies": [
                {
                    "id": 7169,
                    "therapyName": "Omburtamab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT00601003",
            "title": "Study of Nifurtimox to Treat Refractory or Relapsed Neuroblastoma or Medulloblastoma",
            "phase": "Phase II",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 7147,
                    "therapyName": "Cyclophosphamide + Nifurtimox + Topotecan",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT00602667",
            "title": "Risk-Adapted Therapy for Young Children With Embryonal Brain Tumors, Choroid Plexus Carcinoma, High Grade Glioma or Ependymoma",
            "phase": "Phase I",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 2449,
                    "therapyName": "Cisplatin + Cyclophosphamide + Methotrexate + Vincristine",
                    "synonyms": null
                },
                {
                    "id": 2450,
                    "therapyName": "Cyclophosphamide + Etoposide + Topotecan",
                    "synonyms": null
                },
                {
                    "id": 2451,
                    "therapyName": "Cyclophosphamide + Erlotinib + Topotecan",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT00885326",
            "title": "N2007-02:Bevacizumab,Cyclophosphamide,and Zoledronic Acid in Patients W/ Recurrent or Refractory High-Risk Neuroblastoma",
            "phase": "Phase I",
            "recruitment": "Completed",
            "therapies": [
                {
                    "id": 2072,
                    "therapyName": "Bevacizumab + Cyclophosphamide + Zoledronic acid",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT00939770",
            "title": "Crizotinib in Treating Young Patients With Relapsed or Refractory Solid Tumors or Anaplastic Large Cell Lymphoma",
            "phase": "Phase Ib/II",
            "recruitment": "Completed",
            "therapies": [
                {
                    "id": 706,
                    "therapyName": "Crizotinib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT01175356",
            "title": "Induction Therapy Including 131 I-MIBG and Chemotherapy in Treating Patients With Newly Diagnosed High-Risk Neuroblastoma Undergoing Stem Cell Transplant, Radiation Therapy, and Maintenance Therapy With Isotretinoin",
            "phase": "Phase I",
            "recruitment": "Completed",
            "therapies": [
                {
                    "id": 2558,
                    "therapyName": "Busulfan + Melphalan",
                    "synonyms": null
                },
                {
                    "id": 2590,
                    "therapyName": "Cyclophosphamide + Topotecan",
                    "synonyms": null
                },
                {
                    "id": 1425,
                    "therapyName": "131I-MIBG",
                    "synonyms": null
                },
                {
                    "id": 2353,
                    "therapyName": "Cyclophosphamide + Doxorubicin + Vincristine",
                    "synonyms": null
                },
                {
                    "id": 2585,
                    "therapyName": "Cisplatin + Etoposide",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT01241162",
            "title": "Decitabine Followed by a Cancer Antigen Vaccine for Patients With Neuroblastoma and Sarcoma",
            "phase": "Phase I",
            "recruitment": "Completed",
            "therapies": [
                {
                    "id": 650,
                    "therapyName": "Decitabine",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT01331135",
            "title": "Aflac ST0901 CHOANOME - Sirolimus in Solid Tumors",
            "phase": "Phase I",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 917,
                    "therapyName": "Sirolimus",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT01492673",
            "title": "Cyclophosphamide, Topotecan, and Bevacizumab (CTB) in Patients With Relapsed/Refractory Ewing's Sarcoma and Neuroblastoma",
            "phase": "Phase II",
            "recruitment": "Completed",
            "therapies": [
                {
                    "id": 1479,
                    "therapyName": "Bevacizumab + Cyclophosphamide + Topotecan",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT01518413",
            "title": "Dose Escalation Study of Sorafenib and Irinotecan Combination Therapy in Pediatric Patients With Solid Tumors",
            "phase": "Phase I",
            "recruitment": "Completed",
            "therapies": [
                {
                    "id": 1323,
                    "therapyName": "Irinotecan + Sorafenib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT01526603",
            "title": "High Dose Chemotherapy and Autologous Transplant for Neuroblastoma",
            "phase": "Phase I",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 1207,
                    "therapyName": "Melphalan",
                    "synonyms": null
                },
                {
                    "id": 1136,
                    "therapyName": "Etoposide",
                    "synonyms": null
                },
                {
                    "id": 1632,
                    "therapyName": "Filgrastim",
                    "synonyms": null
                },
                {
                    "id": 1877,
                    "therapyName": "Tretinoin",
                    "synonyms": null
                },
                {
                    "id": 1092,
                    "therapyName": "Carboplatin",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT01587703",
            "title": "A Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of GSK525762 in Subjects With NUT Midline Carcinoma (NMC) and Other Cancers",
            "phase": "Phase I",
            "recruitment": "Completed",
            "therapies": [
                {
                    "id": 784,
                    "therapyName": "GSK525762",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT01601535",
            "title": "Study of MLN8237 in Combination With Irinotecan and Temozolomide",
            "phase": "Phase Ib/II",
            "recruitment": "Completed",
            "therapies": [
                {
                    "id": 2628,
                    "therapyName": "Alisertib + Irinotecan + Temozolomide",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT01625351",
            "title": "A Study of CD45RA+ Depleted Haploidentical Stem Cell Transplantation in Children With Relapsed or Refractory Solid Tumors and Lymphomas",
            "phase": "Phase I",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 1166,
                    "therapyName": "Fludarabine",
                    "synonyms": null
                },
                {
                    "id": 1207,
                    "therapyName": "Melphalan",
                    "synonyms": null
                },
                {
                    "id": 1206,
                    "therapyName": "Busulfan",
                    "synonyms": null
                },
                {
                    "id": 1205,
                    "therapyName": "Alemtuzumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT01747876",
            "title": "Study of Safety and Efficacy in Patients With Malignant Rhabdoid Tumors (MRT) and Neuroblastoma",
            "phase": "Phase I",
            "recruitment": "Terminated",
            "therapies": [
                {
                    "id": 790,
                    "therapyName": "Ribociclib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT01757626",
            "title": "Combination Therapy of Antibody Hu3F8 With Granulocyte- Macrophage Colony Stimulating Factor (GM-CSF) in Patients With Relapsed/Refractory High-Risk Neuroblastoma",
            "phase": "Phase Ib/II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 7276,
                    "therapyName": "Naxitamab + Sargramostim",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT01767194",
            "title": "Irinotecan Hydrochloride and Temozolomide With Temsirolimus or Monoclonal Antibody Ch14.18 in Treating Younger Patients With Refractory or Relapsed Neuroblastoma",
            "phase": "Phase II",
            "recruitment": "Completed",
            "therapies": [
                {
                    "id": 2286,
                    "therapyName": "Dinutuximab",
                    "synonyms": null
                },
                {
                    "id": 936,
                    "therapyName": "Temsirolimus",
                    "synonyms": null
                },
                {
                    "id": 1462,
                    "therapyName": "Irinotecan + Temozolomide",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT01822652",
            "title": "3rd Generation GD-2 Chimeric Antigen Receptor and iCaspase Suicide Safety Switch, Neuroblastoma, GRAIN",
            "phase": "Phase I",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 1148,
                    "therapyName": "Cyclophosphamide",
                    "synonyms": null
                },
                {
                    "id": 1166,
                    "therapyName": "Fludarabine",
                    "synonyms": null
                },
                {
                    "id": 1447,
                    "therapyName": "Pembrolizumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT01857934",
            "title": "Therapy for Children With Advanced Stage Neuroblastoma",
            "phase": "Phase II",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 1009,
                    "therapyName": "Doxorubicin",
                    "synonyms": null
                },
                {
                    "id": 1873,
                    "therapyName": "Sargramostim",
                    "synonyms": null
                },
                {
                    "id": 1167,
                    "therapyName": "Aldesleukin",
                    "synonyms": null
                },
                {
                    "id": 1631,
                    "therapyName": "Vincristine",
                    "synonyms": null
                },
                {
                    "id": 1632,
                    "therapyName": "Filgrastim",
                    "synonyms": null
                },
                {
                    "id": 1877,
                    "therapyName": "Tretinoin",
                    "synonyms": null
                },
                {
                    "id": 2627,
                    "therapyName": "Levetiracetam",
                    "synonyms": null
                },
                {
                    "id": 2585,
                    "therapyName": "Cisplatin + Etoposide",
                    "synonyms": null
                },
                {
                    "id": 2458,
                    "therapyName": "Hu14.18K322A",
                    "synonyms": null
                },
                {
                    "id": 2558,
                    "therapyName": "Busulfan + Melphalan",
                    "synonyms": null
                },
                {
                    "id": 2590,
                    "therapyName": "Cyclophosphamide + Topotecan",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT01956669",
            "title": "Pazopanib Paediatric Phase II Trial Children's Oncology Group (COG) in Solid Tumors",
            "phase": "Phase II",
            "recruitment": "Completed",
            "therapies": [
                {
                    "id": 848,
                    "therapyName": "Pazopanib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02013336",
            "title": "Phase 1 Study of MM-398 Plus Cyclophosphamide in Pediatric Solid Tumors",
            "phase": "Phase I",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 7579,
                    "therapyName": "Cyclophosphamide + MM-398",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02030964",
            "title": "N2012-01 Phase 1 Study of Difluoromethylornithine (DFMO) and Celecoxib With Cyclophosphamide/Topotecan",
            "phase": "Phase I",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 2590,
                    "therapyName": "Cyclophosphamide + Topotecan",
                    "synonyms": null
                },
                {
                    "id": 2124,
                    "therapyName": "Celecoxib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02035137",
            "title": "131I-MIBG Alone VS. 131I-MIBG With Vincristine and Irinotecan VS131I-MIBG With Vorinistat",
            "phase": null,
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 1425,
                    "therapyName": "131I-MIBG",
                    "synonyms": null
                },
                {
                    "id": 1426,
                    "therapyName": "131I-MIBG + Irinotecan + Vincristine",
                    "synonyms": null
                },
                {
                    "id": 1427,
                    "therapyName": "131I-MIBG + Vorinostat",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02075177",
            "title": "Expanded Access Study of Fenretinide Lym-X-Sorb Plus Ketoconazole in Neuroblastoma",
            "phase": "Phase I",
            "recruitment": "No longer available",
            "therapies": [
                {
                    "id": 2858,
                    "therapyName": "Ketoconazole",
                    "synonyms": null
                },
                {
                    "id": 2731,
                    "therapyName": "Fenretinide",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02095132",
            "title": "Adavosertib and Irinotecan Hydrochloride in Treating Younger Patients With Relapsed or Refractory Solid Tumors",
            "phase": "Phase Ib/II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 1361,
                    "therapyName": "Adavosertib + Irinotecan",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02100891",
            "title": "Phase 2 STIR Trial: Haploidentical Transplant and Donor Natural Killer Cells for Solid Tumors",
            "phase": "Phase II",
            "recruitment": "Recruiting",
            "therapies": [
                
            ]
        },
        {
            "nctId": "NCT02124772",
            "title": "Study to Investigate Safety, Pharmacokinetic (PK), Pharmacodynamic (PD) and Clinical Activity of Trametinib in Subjects With Cancer or Plexiform Neurofibromas and Trametinib in Combination With Dabrafenib in Subjects With Cancers Harboring V600 Mutations",
            "phase": "Phase I",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 2,
                    "therapyName": "Trametinib",
                    "synonyms": null
                },
                {
                    "id": 1066,
                    "therapyName": "Dabrafenib + Trametinib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02130869",
            "title": "A Pilot Study of Immunotherapy Including Haploidentical NK Cell Infusion Following CD133+ Positively-Selected Autologous Hematopoietic Stem Cells in Children With High Risk Solid Tumors or Lymphomas",
            "phase": "Phase I",
            "recruitment": "Completed",
            "therapies": [
                {
                    "id": 2378,
                    "therapyName": "Bendamustine + Cytarabine + Etoposide",
                    "synonyms": null
                },
                {
                    "id": 2460,
                    "therapyName": "Busulfan + Hu14.18K322A",
                    "synonyms": null
                },
                {
                    "id": 2459,
                    "therapyName": "Aldesleukin + Melphalan + Sargramostim",
                    "synonyms": null
                },
                {
                    "id": 1632,
                    "therapyName": "Filgrastim",
                    "synonyms": null
                },
                {
                    "id": 1791,
                    "therapyName": "Carboplatin + Etoposide",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02139397",
            "title": "Study of DFMO in Combination With Bortezomib for Relapsed or Refractory Neuroblastoma",
            "phase": "Phase Ib/II",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 2629,
                    "therapyName": "Eflornithine",
                    "synonyms": null
                },
                {
                    "id": 688,
                    "therapyName": "Bortezomib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02163356",
            "title": "Fenretinide Lym-X-Sorb + Ketoconazole + Vincristine for Recurrent or Resistant Neuroblastoma",
            "phase": "Phase I",
            "recruitment": "Completed",
            "therapies": [
                {
                    "id": 1631,
                    "therapyName": "Vincristine",
                    "synonyms": null
                },
                {
                    "id": 2731,
                    "therapyName": "Fenretinide",
                    "synonyms": null
                },
                {
                    "id": 2858,
                    "therapyName": "Ketoconazole",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02173093",
            "title": "Activated T Cells Armed With GD2 Bispecific Antibody in Children and Young Adults With Neuroblastoma and Osteosarcoma",
            "phase": "Phase Ib/II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 2058,
                    "therapyName": "Aldesleukin + GD2Bi-a ATC + Sargramostim",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02298348",
            "title": "Sorafenib and Cyclophosphamide/Topotecan in Patients With Relapsed and Refractory Neuroblastoma",
            "phase": "Phase I",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 2360,
                    "therapyName": "Cyclophosphamide + Sorafenib + Topotecan",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02303028",
            "title": "Phase I Dose Escalation Study of Topotecan and Pazopanib in Children With Recurrent/Refractory Solid and CNS Tumours",
            "phase": "Phase Ib/II",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 1469,
                    "therapyName": "Pazopanib + Topotecan",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02304458",
            "title": "Nivolumab With or Without Ipilimumab in Treating Younger Patients With Recurrent or Refractory Solid Tumors or Sarcomas",
            "phase": "Phase Ib/II",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 1627,
                    "therapyName": "Ipilimumab + Nivolumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02311621",
            "title": "Engineered Neuroblastoma Cellular Immunotherapy (ENCIT)-01",
            "phase": "Phase I",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 9766,
                    "therapyName": "CE7R CAR T cells",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02337309",
            "title": "SF1126 for Patients With Relapsed or Refractory Neuroblastoma",
            "phase": "Phase I",
            "recruitment": "Terminated",
            "therapies": [
                {
                    "id": 915,
                    "therapyName": "SF1126",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02372006",
            "title": "Trial of Afatinib in Pediatric Tumours",
            "phase": "Phase Ib/II",
            "recruitment": "Suspended",
            "therapies": [
                {
                    "id": 623,
                    "therapyName": "Afatinib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02378428",
            "title": "MIBG Therapy for Patients With MIBG Avid Tumors",
            "phase": "Phase II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 1425,
                    "therapyName": "131I-MIBG",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02508038",
            "title": "Alpha/Beta CD19+ Depleted Haploidentical Transplantation + Zometa",
            "phase": "Phase I",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 2971,
                    "therapyName": "Zoledronic acid",
                    "synonyms": null
                },
                {
                    "id": 2237,
                    "therapyName": "Fludarabine + Melphalan",
                    "synonyms": null
                },
                {
                    "id": 1207,
                    "therapyName": "Melphalan",
                    "synonyms": null
                },
                {
                    "id": 1843,
                    "therapyName": "Tacrolimus",
                    "synonyms": null
                },
                {
                    "id": 1844,
                    "therapyName": "anti-thymocyte globulin",
                    "synonyms": null
                },
                {
                    "id": 1845,
                    "therapyName": "Mycophenolate mofetil",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02559778",
            "title": "Pediatric Precision Laboratory Advanced Neuroblastoma Therapy",
            "phase": "Phase I",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 688,
                    "therapyName": "Bortezomib",
                    "synonyms": null
                },
                {
                    "id": 706,
                    "therapyName": "Crizotinib",
                    "synonyms": null
                },
                {
                    "id": 787,
                    "therapyName": "Lapatinib",
                    "synonyms": null
                },
                {
                    "id": 1077,
                    "therapyName": "Vorinostat",
                    "synonyms": null
                },
                {
                    "id": 2629,
                    "therapyName": "Eflornithine",
                    "synonyms": null
                },
                {
                    "id": 920,
                    "therapyName": "Sorafenib",
                    "synonyms": null
                },
                {
                    "id": 717,
                    "therapyName": "Dasatinib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02574728",
            "title": "Sirolimus in Combination With Metronomic Chemotherapy in Children With Recurrent and/or Refractory Solid and CNS Tumors",
            "phase": "Phase II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 3143,
                    "therapyName": "Celecoxib + Cyclophosphamide + Etoposide + Sirolimus",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02639546",
            "title": "Safety and Pharmacokinetics of Cobimetinib in Pediatric and Young Adult Participants With Previously Treated Solid Tumors (iMATRIXcobi)",
            "phase": "Phase Ib/II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 1004,
                    "therapyName": "Cobimetinib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02644460",
            "title": "Abemaciclib in Children With DIPG or Recurrent/Refractory Solid Tumors",
            "phase": "Phase I",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 802,
                    "therapyName": "Abemaciclib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02650401",
            "title": "Study Of Entrectinib (Rxdx-101) in Children and Adolescents With No Curative First-Line Treatment Option, Recurrent or Refractory Solid Tumors And Primary Cns Tumors, With or Without Trk, Ros1, or Alk Fusions",
            "phase": "Phase I",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 1455,
                    "therapyName": "Entrectinib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02650648",
            "title": "Humanized Anti-GD2 Antibody Hu3F8 and Allogeneic Natural Killer Cells for High-Risk Neuroblastoma",
            "phase": "Phase I",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 7373,
                    "therapyName": "Aldesleukin + Cyclophosphamide + Naxitamab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02748135",
            "title": "A Two-Part Study of TB-403 in Pediatric Subjects With Relapsed or Refractory Medulloblastoma",
            "phase": "Phase Ib/II",
            "recruitment": "Suspended",
            "therapies": [
                {
                    "id": 4704,
                    "therapyName": "TB-403",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02780128",
            "title": "Next Generation Personalized Neuroblastoma Therapy",
            "phase": "Phase I",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 2186,
                    "therapyName": "HDM201",
                    "synonyms": null
                },
                {
                    "id": 2638,
                    "therapyName": "Ceritinib + Ribociclib",
                    "synonyms": null
                },
                {
                    "id": 2,
                    "therapyName": "Trametinib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02789228",
            "title": "Research Study Utilizing Expanded Multi-antigen Specific Lymphocytes for the Treatment of Solid Tumors (REST)",
            "phase": "Phase I",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 9602,
                    "therapyName": "MultiTAA-specific T cells",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02909777",
            "title": "Trial of CUDC-907 in Children and Young Adults With Relapsed or Refractory Solid Tumors, CNS Tumors, or Lymphoma",
            "phase": "Phase I",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 709,
                    "therapyName": "CUDC-907",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02982941",
            "title": "Enoblituzumab (MGA271) in Children With B7-H3-expressing Solid Tumors",
            "phase": "Phase I",
            "recruitment": "Completed",
            "therapies": [
                {
                    "id": 2863,
                    "therapyName": "MGA271",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03033303",
            "title": "A Study of the Effect of Hu3F8/GM-CSF Immunotherapy Plus Isotretinoin in Patients in First Remission of High-Risk Neuroblastoma",
            "phase": "Phase II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 7374,
                    "therapyName": "Isotretinoin + Naxitamab + Sargramostim",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03107988",
            "title": "Study of Lorlatinib (PF-06463922)",
            "phase": "Phase I",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 5580,
                    "therapyName": "Cyclophosphamide + Lorlatinib + Topotecan",
                    "synonyms": null
                },
                {
                    "id": 869,
                    "therapyName": "Lorlatinib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03126916",
            "title": "Iobenguane I-131 or Crizotinib and Standard Therapy in Treating Younger Patients With Newly-Diagnosed High-Risk Neuroblastoma or Ganglioneuroblastoma",
            "phase": "Phase III",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 1009,
                    "therapyName": "Doxorubicin",
                    "synonyms": null
                },
                {
                    "id": 1425,
                    "therapyName": "131I-MIBG",
                    "synonyms": null
                },
                {
                    "id": 1873,
                    "therapyName": "Sargramostim",
                    "synonyms": null
                },
                {
                    "id": 1136,
                    "therapyName": "Etoposide",
                    "synonyms": null
                },
                {
                    "id": 1207,
                    "therapyName": "Melphalan",
                    "synonyms": null
                },
                {
                    "id": 1206,
                    "therapyName": "Busulfan",
                    "synonyms": null
                },
                {
                    "id": 5595,
                    "therapyName": "Isotretinoin",
                    "synonyms": null
                },
                {
                    "id": 1631,
                    "therapyName": "Vincristine",
                    "synonyms": null
                },
                {
                    "id": 700,
                    "therapyName": "Cisplatin",
                    "synonyms": null
                },
                {
                    "id": 1148,
                    "therapyName": "Cyclophosphamide",
                    "synonyms": null
                },
                {
                    "id": 2563,
                    "therapyName": "Thiotepa",
                    "synonyms": null
                },
                {
                    "id": 706,
                    "therapyName": "Crizotinib",
                    "synonyms": null
                },
                {
                    "id": 5153,
                    "therapyName": "Dexrazoxane",
                    "synonyms": null
                },
                {
                    "id": 1092,
                    "therapyName": "Carboplatin",
                    "synonyms": null
                },
                {
                    "id": 1167,
                    "therapyName": "Aldesleukin",
                    "synonyms": null
                },
                {
                    "id": 942,
                    "therapyName": "Topotecan",
                    "synonyms": null
                },
                {
                    "id": 2286,
                    "therapyName": "Dinutuximab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03155620",
            "title": "Targeted Therapy Directed by Genetic Testing in Treating Pediatric Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphomas, or Histiocytic Disorders (The Pediatric MATCH Screening Trial)",
            "phase": "Phase II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 2683,
                    "therapyName": "Tazemetostat",
                    "synonyms": null
                },
                {
                    "id": 2650,
                    "therapyName": "Larotrectinib",
                    "synonyms": null
                },
                {
                    "id": 1069,
                    "therapyName": "LY3023414",
                    "synonyms": null
                },
                {
                    "id": 342,
                    "therapyName": "Vemurafenib",
                    "synonyms": null
                },
                {
                    "id": 850,
                    "therapyName": "Palbociclib",
                    "synonyms": null
                },
                {
                    "id": 837,
                    "therapyName": "Olaparib",
                    "synonyms": null
                },
                {
                    "id": 997,
                    "therapyName": "Ulixertinib",
                    "synonyms": null
                },
                {
                    "id": 1028,
                    "therapyName": "Erdafitinib",
                    "synonyms": null
                },
                {
                    "id": 913,
                    "therapyName": "Selumetinib",
                    "synonyms": null
                },
                {
                    "id": 961,
                    "therapyName": "Ensartinib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03189706",
            "title": "Pilot Study of Chemoimmunotherapy for High-Risk Neuroblastoma",
            "phase": "Phase I",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 7378,
                    "therapyName": "Irinotecan + Naxitamab + Sargramostim + Temozolomide",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03209869",
            "title": "Treatment of Relapsed or Refractory Neuroblastoma With Expanded Haploidentical NK Cells and Hu14.18-IL2",
            "phase": "Phase I",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 8413,
                    "therapyName": "hu14.18-IL2",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03210714",
            "title": "Erdafitinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With FGFR Mutations (A Pediatric MATCH Treatment Trial)",
            "phase": "Phase II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 1028,
                    "therapyName": "Erdafitinib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03213652",
            "title": "Ensartinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With ALK or ROS1 Genomic Alterations (A Pediatric MATCH Treatment Trial)",
            "phase": "Phase II",
            "recruitment": "Suspended",
            "therapies": [
                {
                    "id": 961,
                    "therapyName": "Ensartinib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03213678",
            "title": "PI3K/mTOR Inhibitor LY3023414 in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With TSC or PI3K/MTOR Mutations (A Pediatric MATCH Treatment Trial)",
            "phase": "Phase II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 1069,
                    "therapyName": "LY3023414",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03213691",
            "title": "Selumetinib Sulfate in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With Activating MAPK Pathway Mutations (A Pediatric MATCH Treatment Trial)",
            "phase": "Phase II",
            "recruitment": "Suspended",
            "therapies": [
                {
                    "id": 913,
                    "therapyName": "Selumetinib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03213704",
            "title": "Larotrectinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With NTRK Fusions (A Pediatric MATCH Treatment Trial)",
            "phase": "Phase II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 2650,
                    "therapyName": "Larotrectinib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03233204",
            "title": "Olaparib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With Defects in DNA Damage Repair Genes (A Pediatric MATCH Treatment Trial)",
            "phase": "Phase II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 837,
                    "therapyName": "Olaparib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03363373",
            "title": "Naxitamab for Neuroblastoma With Osteomedullary Disease",
            "phase": "Phase III",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 7276,
                    "therapyName": "Naxitamab + Sargramostim",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03458728",
            "title": "Safety, Tolerability, Efficacy and Pharmacokinetics of Copanlisib in Pediatric Patients",
            "phase": "Phase Ib/II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 995,
                    "therapyName": "Copanlisib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03478462",
            "title": "Dose Escalation Study of CLR 131 in Children and Adolescents With Relapsed or Refractory Malignant Brain Cancer, Neuroblastoma, Rhabdomyosarcoma, Ewings Sarcoma, and Osteosarcoma",
            "phase": "Phase I",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 7331,
                    "therapyName": "CLR 131",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03526250",
            "title": "Palbociclib in Treating Patients With Relapsed or Refractory Rb Positive Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With Activating Alterations in Cell Cycle Genes (A Pediatric MATCH Treatment Trial)",
            "phase": "Phase II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 850,
                    "therapyName": "Palbociclib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03581240",
            "title": "An Intermediate Expanded Use Trial of DFMO",
            "phase": "Expanded access",
            "recruitment": "Available",
            "therapies": [
                {
                    "id": 2629,
                    "therapyName": "Eflornithine",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03635632",
            "title": "C7R-GD2.CART Cells for Patients With Relapsed or Refractory Neuroblastoma and Other GD2 Positive Cancers (GAIL-N)",
            "phase": "Phase I",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 9563,
                    "therapyName": "C7R-GD2.CART cells",
                    "synonyms": null
                },
                {
                    "id": 2291,
                    "therapyName": "Cyclophosphamide + Fludarabine",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03698994",
            "title": "Ulixertinib in Treating Patients With Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With MAPK Pathway Mutations (A Pediatric MATCH Treatment Trial)",
            "phase": "Phase II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 997,
                    "therapyName": "Ulixertinib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03709680",
            "title": "Study Of Palbociclib Combined With Chemotherapy In Pediatric Patients With Recurrent/Refractory Solid Tumors",
            "phase": "Phase I",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 8371,
                    "therapyName": "Irinotecan + Palbociclib + Temozolomide",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT04029688",
            "title": "A Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Preliminary Activity of Idasanutlin in Combination With Either Chemotherapy or Venetoclax in the Treatment of Pediatric and Young Adult Participants With Relapsed/Refractory Acute Leukemias or Solid Tumors",
            "phase": "Phase Ib/II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 8616,
                    "therapyName": "Idasanutlin + Venetoclax",
                    "synonyms": null
                },
                {
                    "id": 8617,
                    "therapyName": "Cyclophosphamide + Idasanutlin + Topotecan",
                    "synonyms": null
                },
                {
                    "id": 8621,
                    "therapyName": "Cytarabine + Fludarabine + Idasanutlin",
                    "synonyms": null
                },
                {
                    "id": 8175,
                    "therapyName": "Cytarabine + Hydrocortisone + Methotrexate",
                    "synonyms": null
                },
                {
                    "id": 712,
                    "therapyName": "Cytarabine",
                    "synonyms": null
                },
                {
                    "id": 1639,
                    "therapyName": "Methotrexate",
                    "synonyms": null
                },
                {
                    "id": 2023,
                    "therapyName": "Idasanutlin",
                    "synonyms": null
                },
                {
                    "id": 8626,
                    "therapyName": "Cyclophosphamide + Idasanutlin",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT04106219",
            "title": "A Study of LY3295668 Erbumine in Participants With Relapsed/Refractory Neuroblastoma",
            "phase": "Phase I",
            "recruitment": "Not yet recruiting",
            "therapies": [
                {
                    "id": 5753,
                    "therapyName": "LY3295668",
                    "synonyms": null
                },
                {
                    "id": 8782,
                    "therapyName": "Cyclophosphamide + LY3295668 + Topotecan",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT04239040",
            "title": "GVAX Plus Checkpoint Blockade in Neuroblastoma",
            "phase": "Phase I",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 9278,
                    "therapyName": "GVAX + Ipilimumab + Nivolumab",
                    "synonyms": null
                }
            ]
        }
    ]
}